Pdx-1 modulates endoplasmic reticulum calcium homeostasis in the islet β cell via transcriptional enhancement of SERCA2b by Johnson, Justin Sean
PDX-1 MODULATES ENDOPLASMIC RETICULUM CALCIUM HOMEOSTASIS 
IN THE ISLET β CELL VIA TRANSCRIPTIONAL ENHANCEMENT OF 
SERCA2B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Justin Sean Johnson 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Submitted to the faculty of the University Graduate School  
in partial fulfillment of the requirements 
for the degree 
Doctor of Philosophy 
in the Department of Biochemistry and Molecular Biology, 
Indiana University 
 
December 2014 
  
   
 
Accepted by the Graduate Faculty, of Indiana University, in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy. 
 
 
 
_______________________________________ 
Carmella Evans-Molina, M.D., Ph.D., Chair  
 
 
_______________________________________ 
Jeffrey S. Elmendorf, Ph.D.    
Doctoral Committee 
 
_______________________________________ 
Robert A. Harris, Ph.D.     
 
May 9, 2014 
_______________________________________ 
Raghuvendra G. Mirmira, M.D., Ph.D.   
 
 
 
  
ii 
 
Dedication 
This dissertation is dedicated to my wife, Amy, who has supported me through 
every triumph and every adversity.  
“A loving heart is the beginning of all knowledge.” – Thomas Carlyle 
 
  
iii 
 
Acknowledgements 
I would like to give special thanks to Carmella Evans-Molina, Raghu Mirmira, and 
Maureen Harrington, who together gave me a second chance to prove my dedication 
and determination to earn this degree, and without whom this thesis would have never 
been written. Thanks also to Robert Harris, who has mentored me every step of the way. 
I would like to thank the members of my committee, including Jeff Elmendorf, who is not 
only an excellent scientist and metabolism expert, but also a mentor and tireless 
advocate for so many graduate students. 
In addition to those mentioned above, I would like to thank Dr. Robert Bacallao, who 
has advised me on how to be not only a physician and scientist, but a great one; and Dr. 
Thor Johnson, without whom I would not have chosen this path. I also thank Andy 
Hudmon, Mark Goebl and Jeffrey Travers for encouraging me in pursuing my scientific 
passion of translational research. I would also like to thank Simon Atkinson, Bruce 
Molitoris and Lawrence Quilliam for their guidance. 
I would like to thank the Medical Scientist Training Program (MSTP) and all of those 
who so freely give of their busy schedules to make it the stellar program that it is. I 
especially note the sacrifice and dedication of the co-directors, Maureen Harrington and 
Raghu Mirmira, and of course the indefatigable Jan Receveur. I would also like to 
acknowledge and thank the former MSTP co-director Dr. Wade Clapp, and the generous 
funding provided for the MSTP by the Ruth Lilly Foundation.  
The Diabetes Research Group is more than just a collection of co-located 
laboratories; the members of the group genuinely care for one another, and no student 
could go lacking for friendship, advice or support within the group. to the entire group: I 
thank you, and thank you as well to the Wells Center for Pediatric Research of which the 
Diabetes Research Group is one part. 
iv 
 
I would like to acknowledge the diversity supplement provided to Carmella Evans-
Molina on my behalf by the NIDDK of the National Institutes of Health for my financial 
support. I have also been generously supported by the Indiana University School of 
Medicine MSTP on multiple occasions, for which I am truly grateful.  
I would like to thank my professors for their instruction and assistance. The 
Department of Biochemistry and Molecular Biology is a supportive environment for 
students and I thank the department for the opportunities they have provided me. The 
Department of Medicine has supported the laboratories I have worked in these past five 
years, and I would like to thank the department as a whole but perhaps especially the 
Nephrology and Endocrinology Divisions. 
I would also like to thank the Translational Research journal as well as The Journal 
of Biological Chemistry for giving me the opportunity to publish my scientific writing and 
research. 
And finally, and most importantly, thank you once again to Carmella Evans-Molina, 
who is a daily inspiration, and whom I hope to emulate as I pursue a career in medical 
science. 
  
v 
 
Justin Sean Johnson 
 
PDX-1 MODULATES ENDOPLASMIC RETICULUM CALCIUM HOMEOSTASIS IN THE 
ISLET β CELL VIA TRANSCRIPTIONAL ENHANCEMENT OF SERCA2B 
 
Diabetes mellitus (DM) affects an estimated 285 million people worldwide, and a 
central component of diabetes pathophysiology is diminished pancreatic islet β cell 
function resulting in the inability to manage blood glucose effectively. The β cell is a 
highly specialized metabolic factory that possesses a number of specialized 
characteristics, chief among these a highly developed endoplasmic reticulum (ER). The 
sarco endoplasmic reticulum Ca2+ ATPase 2b (SERCA2b) pump maintains a steep Ca2+ 
gradient between the cytosol and ER lumen, and while the Pancreatic and duodenal 
homeobox 1 (Pdx-1) transcription factor is known to play an indispensable role in β cell 
development and function, recent data also implicate Pdx-1 in the maintenance of ER 
health. Our data demonstrates that a decrease of β cell Pdx-1 occurs in parallel with 
decreased SERCA2b expression in models of diabetes, while in silico analysis of the 
SERCA2b promoter revealed multiple putative Pdx-1 binding sites. We hypothesized 
that Pdx-1 loss under inflammatory and diabetic conditions leads to decreased 
SERCA2b with concomitant alterations in ER health.  
To test this, siRNA-mediated knockdown of Pdx-1 was performed in INS-1 cells. 
Results revealed reduced SERCA2b expression and decreased ER Ca2+, which was 
measured using an ER-targeted D4ER adenovirus and fluorescence lifetime imaging 
microscopy. Co-transfection of human Pdx-1 with a reporter fused to the human 
SERCA2 promoter increased luciferase activity three-fold relative to the empty vector 
control, and direct binding of Pdx-1 to the proximal SERCA2 promoter was confirmed by 
chromatin immunoprecipitation. To determine whether restoration of SERCA2b could 
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rescue ER stress induced by Pdx-1 loss, Pdx1+/- mice were fed high fat diet for 8 weeks. 
Isolated islets from these mice demonstrated increased expression of spliced Xbp1, 
signifying ER stress, while subsequent SERCA2b overexpression in isolated islets 
reduced spliced Xbp1 levels to that of wild-type controls. These results identify 
SERCA2b as a direct transcriptional target of Pdx-1 and define a novel role for altered 
ER Ca2+ regulation in Pdx-1 deficient states. 
Future studies will investigate the interaction of Pdx-1 with other transcription factors 
at the SERCA2 promoter, particularly peroxisome proliferator-activated receptor gamma 
and forkhead box protein O1. 
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Chapter I. Introduction 
I.A. Diabetes Mellitus 
Diabetes mellitus (DM)  is a metabolic disorder characterized by chronically elevated 
blood glucose due to a relative or complete deficiency of insulin [1]. Insulin is a peptide 
hormone synthesized and released by the β cells of the pancreas, and its physiological 
effects include stimulation of glucose uptake in peripheral tissues, inhibition of hepatic 
gluconeogenesis, and growth stimulation [2]. Diabetes mellitus is divided into two major 
types designated as Type 1 diabetes mellitus (T1DM), which is characterized by 
autoimmune etiology, insulin dependence, and potentially life-threatening symptoms at 
diagnosis and Type 2 diabetes mellitus (T2DM), which is characterized by 
hyperinsulinemia and is correlated with increased age and body mass index [3].  Chronic 
hyperglycemia in both forms of DM leads to osmotic imbalance, microvascular damage, 
peripheral nerve impairment and potentially lethal effects on the cardiovascular and 
renal systems [1, 4, 5].  
In 2010 DM was the 7th leading cause of mortality in the United States (Figure 1), 
and it also contributed to seven of the remaining top ten causes [5]. Over 25 million 
Americans were estimated to be affected by diabetes mellitus in 2011 with an 
approximate net economic cost exceeding $174 billion per year in the United States 
alone [1]. According to the World Health Organization, by the year 2025 there will be 
more than 380 million people worldwide living with DM, while an additional 418 million 
people will have impaired glucose tolerance or pre-diabetes [6]. Understanding the 
pathophysiology of DM in order to design better strategies for treatment and prevention 
is crucial to public health in the United States and worldwide. 
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Figure 1. Ten Most Common Causes of Mortality in the United States, 2010. 
Diabetes mellitus was the 7th leading cause of death in the United States in the year 
2010. DM also has an established link to heart disease, cancer, stroke, Alzheimer’s 
disease, and kidney disease. Recent research suggests that DM has a link to respiratory 
disease and pneumonia as well. 
  
2 
 
I.A.1. History of Diabetes Mellitus 
The first recorded reference to a syndrome including excess urination was by ancient 
Egyptians in approximately 1500 BCE., but polyuric syndromes were first called 
“diabetes” by the 1st century Greek physician Araetus of Cappodocia [7].  The first 
diabetes cases recorded occurred in children and adults who were not observed to be 
overweight which suggests an autoimmune etiology, but cases of diabetes in adults with 
above average body fat were also recorded [7, 8]. Prior to the 20th century, there were 
no effective treatments for diabetes.  
Although physicians could readily diagnose and differentiate DM from other polyuric 
syndromes, the etiology of DM was not understood until the 19th century. Prior to that 
time proposed causes were manifold, including emotional excitability, temperature 
changes, and socially unacceptable behaviors [7]. The discovery by French biochemist 
and physiologist Claude Bernard that the liver was capable of synthesizing 
carbohydrates was the first substantiation of the liver’s role in DM [9]. Prior to Bernard’s 
discovery of glycogen it had been thought that carbohydrates were of exclusively 
vegetable origin [10], and therefore the understanding that animals were capable of 
glucose synthesis was a significant conceptual advance relevant to DM. 
The discovery that provided the first evidence for the pancreatic role in DM was the 
observation of a dog’s repeated urination on a laboratory floor. The animal had been 
recently pancreatectomized, and when physiologist Oskar Minkowski tested the dog’s 
urine he found that it contained a high concentration of glucose. Repeated experiments 
involving pancreatectomy confirmed the finding of glycosuria, for the first time linking the 
pancreas with a pathognomonic symptom of diabetes mellitus [7]. 
After Minkowski’s discovery of the link between DM and the pancreas became widely 
known, physiologists sought to understand how the pancreas controlled glucose levels in 
the blood. Investigators at the University of Toronto including Fredrick Banting, Charles 
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Best, James J. R. MacLeod, and James B. Collip hypothesized that an extract of animal 
pancreas could be given to diabetic persons to control blood glucose, and they directed 
their efforts towards isolating and purifying this unknown substance. Eventually Banting, 
Best, MacLeod and Collip developed a protocol to isolate a pancreatic extract they 
named “insulin” which reduced blood glucose when injected into pancreatectomized 
dogs. Isolated animal insulin was subsequently found to lower blood glucose in diabetic 
humans [11, 12]. Refinement of the insulin isolation process soon led to what was 
considered at the time to be a “miraculous” reversal of this fatal disease, and the modern 
era of insulin treatment for  DM began in the year 1922 [13]. 
 
I.A.2. Classification of Diabetes Mellitus 
Diabetes mellitus is divided into two major types as well as other less prevalent 
types. The two largest categories of diabetes mellitus are Type 1 (T1DM) and Type 2 
(T2DM). T2DM is most prevalent in the United States, comprising approximately 90-95% 
of DM cases with T1DM making up the majority of the remaining 5-10% [1, 14]. Types of 
diabetes mellitus not categorized as either Type 1 or Type 2 include Gestational 
diabetes mellitus (GDM), which occurs in pregnancy [15], Neonatal diabetes mellitus 
(NDM) in infants [16], single-gene mutations causing Maturity Onset Diabetes of the 
Young (MODY)  [17], as well as other less prevalent forms including: monogenic and 
polygenic congenital DM syndromes, “bronze diabetes” due to hemochromatosis, cystic 
fibrosis related DM, or DM due to additional factors including drug or steroid use or 
abuse, trauma of the exocrine pancreas, β cell mitochondrial disorders, and defects in 
the insulin receptor [3, 18, 19]. Despite increased understanding of the mechanisms of 
DM as well as multiple potential treatments available, the incidence of both T1DM and 
T2DM are increasing each year throughout the world [4, 20]. 
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T1DM is caused by autoimmune-mediated destruction of the β cell population in the 
pancreatic islets of Langerhans [3, 4, 21], and is characterized by nearly complete loss 
of insulin secretion [4]. T1DM differs from T2DM primarily by the symptom of 
hypoinsulinemia, although individuals with advanced T2DM may also lack the ability to 
secrete adequate insulin [22]. T1DM may have a rapid onset of only a few months, or 
residual β cell function may remain for years or decades prior to the necessity for 
exogenous insulin supplementation [3]. Polygenic heritability factors including HLA-
subtype can be used to predict T1DM in certain sub-populations, with detection of T1DM 
primarily occurring via serum testing for syndrome-specific auto-antibodies.  T2DM 
results from a combination of insulin resistance at the level of the adipose, skeletal 
muscle, and liver, impaired gluconeogenesis and insufficient insulin secretion from the 
endocrine pancreas [23, 24]. 
In obese individuals the prodrome of pre-diabetes includes a state of chronic insulin 
resistance in peripheral tissues [25-28]. The first stage of insulin resistance was 
originally observed to be due to nutrient surfeit primarily affecting adipocytes, 
hepatocytes and skeletal muscle myocytes [29]. As measured serum levels of free fatty 
acids increased an initial compensatory hyperinsulinemia resulted. When insulin 
hypersecretion compensation fails to suppress serum free fatty acid levels, susceptible 
individuals progress to fasting hyperglycemia and T2DM [30]. After these initial 
observations, a previously unappreciated aspect of T2DM was that in obesity systemic 
inflammation also contributes to insulin resistance [29]. This adipose tissue inflammation 
bears a strong correlation with obesity, but not all persons with obesity-associated 
inflammation become diabetic [31]. Thus it was determined that obesity and 
inflammation contribute to insulin resistance, and that insulin resistance plays a role in 
the onset of T2DM, yet insulin resistance is not the sole causative factor [29, 32-38].  
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I.A.3. Diagnosis and Treatment of Diabetes Mellitus 
The symptoms of untreated T1DM and T2DM are quite different, although they do 
share some common features. Symptoms of T1DM are generally more obvious than 
T2DM and often include excessive urination (polyuria), excessive thirst (polydipsia), 
excessive hunger (polyphagia), unexplained weight loss, a “fruity” odor on the breath, 
and diabetic ketoacidosis – which can cause coma, seizure, and death [4, 39]. In 
contrast, persons with T2DM may display no overt symptoms initially [1], but when they 
do experience symptoms excessive urination (polyuria), excessive thirst (polydipsia), 
fatigue (anergy), and depression [40] are the most common complaints. Because T2DM 
symptoms can be subtle or may be attributed to other etiologies by healthcare 
practitioners, those with T2DM are often diagnosed due to health screening rather than 
by symptomology [39]. 
The American Diabetes Association, in conjunction with other international health 
organizations, has defined the following criteria for diagnosis of either T1DM or T2DM: a 
hemoglobin A1C (HbA1C) value of >6.5%, fasting plasma glucose concentration ≥126 
mg/dL, plasma glucose concentration >200 mg/dL two hours after intake of 75 g oral 
glucose solution (oral glucose tolerance test, or OGTT), or random blood glucose 
concentration (RBG) >200 mg/dL in a person with other hyperglycemic symptoms. 
Repeat testing is preferable if the individual does not display excessive hyperglycemia or 
overt diabetic symptoms at the time of testing [39]. 
The two most prevalent types of DM have different etiologies and require different 
standards of care. Treatment of T1DM focuses on replacing insulin, while initial 
treatment of T2DM focuses on improving insulin sensitivity and preserving functional β 
cell mass [39]. 
Prior to the advent of exogenous insulin supplementation, the threshold for 
successful treatment of diabetes was considered to be the cessation of excess sugar 
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excretion in the urine [10]. It is now known that glucose is not detectable in the urine 
below a blood glucose level of approximately 200 mg/dL, but health outcomes are 
improved if blood glucose levels are maintained at significantly lower levels.  Although 
blood glucose targets should be adjusted by a physician on an individual basis, for most 
diabetic individuals the recommended targets include: hemoglobin A1c (HbA1C) level of 
less than 7%, preprandial capillary glucose concentration of 70-130 mg/dL, and a 
maximal postprandial capillary glucose concentration of 180 mg/dL [39, 41]. For 
approximating chronic levels of blood glucose over a 90-day period, the HbA1C test was 
developed to measure glycated proteins, and maintenance of HbA1c levels below 7% is 
considered optimal in most adults [42, 43]. The standard of care for DM includes regular 
blood glucose monitoring and HbA1c testing at least quarterly [39, 44, 45]. 
Treatment of T1DM primarily consists of rigorous blood glucose management by 
controlling dietary carbohydrate intake and supplementing β cell insulin secretion with 
exogenous insulin [39, 46]. Automated electronic insulin pumps are available, with the 
most recent generation of insulin pumps and glucometers able to communicate 
wirelessly thereby simplifying T1DM management [47].  It is anticipated that in the near 
future a “closed-loop” combination glucometer and insulin pump will be available [48-50], 
but until such a device is available the current method of dietary control, regular 
measurement of blood glucose, and injection of exogenous insulin remains the preferred 
method to manage T1DM [51]. 
Similar to persons with T1DM, persons with T2DM must monitor carbohydrate intake 
and regularly measure blood glucose. Although the first line treatment for T2DM is 
altering diet and increasing exercise, due to compliance issues diet and exercise 
interventions alone are rarely successful [52-54], and so pharmaceuticals to enhance 
insulin sensitivity or increase insulin secretion are also usually prescribed [46, 55]. The 
majority of people with T2DM do not initially require exogenous insulin supplementation 
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[56], but with time T2DM can worsen such that some persons develop a T1DM-like 
dependence on exogenous insulin [53, 57, 58]. 
 
I.B. Pancreatic Islets and the β Cell 
The multiple types of cells responsible for the endocrine function of the pancreas are 
located in micro-organs embedded throughout the head, tail and body of the pancreas 
[59]. The “Islets of Langerhans” were first described as resembling islands by the 
medical student Paul Langerhans in 1869 [60, 61]. Endocrine islets are found in the 
pancreata of vertebrate animals, but insulin has been found in most animal species 
whether they have a pancreas or not [62, 63]. Pancreatic islets are surrounded by a 
membrane defining a boundary from the surrounding non-endocrine pancreatic cells, 
and islets are well supplied with blood via extensive capillaries passing within and 
throughout the islet [64, 65]. This high degree of vascularity allows the endocrine cells in 
the islet to actively sense signals from, and secrete signals into, the blood [66]. 
The β cell is one of five types of endocrine cells found in the islets of Langerhans. 
The other islet cell types – α, δ, PP and ε cells – secrete glucagon, somatostatin, 
pancreatic polypeptide and ghrelin, respectively [67, 68], but the β cell is the only 
physiologically relevant source of insulin in higher vertebrates [2]. Islet structure differs 
between organisms, for example the non-β cells of the islet surround the periphery of a 
mouse islet, while islet non-β cells are randomly distributed in the islet of a human [69]. 
Pancreatic β cells make up the majority of cells within pancreatic islets, with β cells 
comprising approximately 70-80% of the islet in humans [70]. 
 
I.B.1. β Cell Development and Proliferation 
Although this work does not relate directly to β cell development or proliferation, an 
understanding of islet development is relevant to a full understanding of the signaling 
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pathways involved. The embryonic pancreas initially differentiates from the primitive 
intestinal endoderm. The pancreas develops into three distinct cellular sub-types: acinar 
cells, ductal cells, and endocrine cells [71, 72]. Differentiated acinar cells and ductal cells 
have a negligible effect on DM, but the pancreatic islets are indispensable to 
physiological management of metabolism [65]. When the pancreas is fully formed the 
endocrine islets form less than 3% of the total mass of the pancreas [65, 73, 74]. All five 
islet cell types differentiate from a common islet precursor cell, but the β cells express 
transcription factors that specifically regulate glucose sensing and insulin production and 
secretion.  The maintenance of the expression of these β cell idiomatic proteins as well 
as the suppression of non-β cell genes is necessary for maintenance of euglycemia [75], 
as dedifferentiation of β cells and a corresponding decrease in insulin secretion has 
recently been suggested to contribute to the etiology of T2DM [76, 77].  
Animal models do not perfectly replicate the behaviors and characteristics of human 
β cells. For example β cells continue to proliferate throughout the lifetime of a rodent, but 
human β cells do not [78]. The result is that in rodents pancreatic β cell population 
increases with age and generally corresponds to the overall size of the body for non-
diabetic animals [79, 80]. Interestingly, in mouse models an increase in the rate of β cell 
proliferation is the first response to hyperglycemia, however when proliferation becomes 
impaired frank DM is the result [81]. Restoration of β cell proliferation ameliorates 
hyperglycemia and reverses DM in mice, however [82, 83]. The β cell populations in the 
pancreata of rodents also increase during pregnancy, however this increased 
proliferation ceases with parturition after which the additional β cells involute [84]. 
There are a number of key differences between humans and rodents with respect to 
β cell proliferation. In humans the β cells proliferate most rapidly in the gestational period 
just after initial pancreatic development, but β cell proliferation decreases to less than 
5% of embryonic levels by six months of age [85]. In humans β cell proliferation 
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generally ceases during the third decade of life, but pancreatic β cell replication has 
been observed in adult human pancreata under certain circumstances [86-88]. For 
example, in an attempt to maintain normal physiological concentrations of blood glucose 
under insulin resistant conditions, the β cell’s response to hyperglycemia is to increase 
insulin secretion via an increase in both size and number [82, 89-93]. In a recent study of 
cadaveric pancreata in both lean and obese persons it was found that obese persons 
had approximately 50% greater β cell mass compared to lean persons, and that this 
increase was due to a greater number of β cells [94]. Another notable exception to the 
relative lack of β cell proliferation in adult humans is pregnancy, since β cells in pregnant 
human females also proliferate [95]. As observed with rodents, the hormonal milieu of 
pregnancy stimulates proliferation of β cells in the pancreas of the pregnant female, but 
the nature of the proliferation differs. In human females the increase in β cell mass is 
due to an increased number of new, smaller islets, and unlike rodents evidence of post-
partum islet remodeling via β cell apoptosis in post-partum human females has not been 
observed  [96, 97]. 
Although the intracellular mechanism for β cell expansion has not been fully 
explained [98], certain hormones are known to play a role in β cell compensatory 
proliferation. Pancreatic β cells express receptors for growth hormone (GH) and insulin-
like growth factor 1 (IGF-1), and the effect of hyperglycemia on β cell GH receptor 
knockouts shows that a lack of GH signaling in the β cell under hyperglycemic conditions 
results a lack of compensatory β cell hyperplasia [99]. An example of cell-cell signaling 
contributing to β cell proliferation is epidermal growth factor receptor (EGFR) signaling, 
which is required to form β cells in utero and it is also required for β cell compensatory 
proliferation with obesity or pregnancy [90]. 
In addition to proliferation, β cells also respond to hyperglycemia by increasing in 
diameter. Pancreatic β cell hypertrophy is a pro-survival response, and it is accompanied 
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by pro-survival gene upregulation [100]. As with proliferation there is hormonal signaling 
leading to β cell hypertrophy, specifically GLP-1 signaling [82]. Despite increased β cell 
function with hypertrophy, β cell survival is relatively impaired with larger size [91]. This 
may reflect the activation of pathways that favor survival over function, or it may be due 
to decreased resiliency of the individual β cell related to cell size [101], but β cell 
hypertrophy is primarily only suitable as a temporizing adaptation [91]. 
Unfortunately in DM-susceptible individuals pancreatic β cell proliferation and 
hypertrophy are insufficient to prevent disease progression [102]. So long as the β cells 
are capable of secreting sufficient insulin to dispose of excess blood glucose the 
individual will not progress to frank diabetes, but if β cell compensation should fail then 
the individual will progress from impaired glucose tolerance and hyperinsulinemia to 
uncontrolled hyperglycemia and DM [91]. 
 
I.B.2. β Cell Function and Insulin Secretion 
Essential to the function of the pancreatic β cell is the ability to sense and respond to 
elevated blood glucose levels [103]. All cells in the body are able to take up glucose from 
the blood, however specialized glucose transporter proteins GLUT1 and GLUT2 ensure 
that the β cell is more sensitive to basal blood glucose levels than other cell types [104, 
105]. Once glucose enters the pancreatic β cell it is phosphorylated by the enzyme 
glucokinase (GCK), both to begin the process of glycolysis and also to prevent the 
glucose from leaving the β cell [106]. Glycolysis begins in the cytoplasm but the 
mitochondria synthesize the majority of the energetic intermediate adenosine 
triphosphate (ATP) via enzymatic oxidation of molecules derived from the original 
glucose molecule [107]. The resultant increase in cellular ATP concentration triggers 
calcium flow into the cytoplasm from the extracellular space via ATP-linked potassium 
(KATP) ion channels [108], after which the calcium influx stimulates exocytosis of 
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perimembrane insulin granules and the first phase insulin response [103]. Blood glucose 
sensing and subsequent calcium signaling stimulate increased insulin synthesis, insulin 
processing, and insulin secretion, which leads to the second sustained phase of insulin 
response [109]. Glucose and calcium signaling in the β cell are inseparably connected to 
the ability of the β cell to maintain euglycemia. 
Glucose is not the only trigger for β cell insulin secretion. Since depolarization of the 
β cell relies on KATP ion channels, extracellular increases in potassium concentration 
can cause depolarization and insulin release [110]. Potassium-stimulated insulin release 
(KSIS) is not suitable as a DM treatment modality [111], and thus KSIS is better 
understood as a tool for in vitro investigations of β cell function. Free fatty acids (FFAs) 
are another fuel source taken up from the blood by the β cell, and β cells secrete insulin 
in response to elevated serum FFAs [112]. FFAs are not an optimal fuel source for the β 
cell however because chronic lipid catabolism depletes the β cell of insulin [113]. Other 
simple sugars also stimulate insulin secretion, as fructose causes insulin secretion from 
the β cell albeit with a time delay compared to glucose [114, 115]. Pharmaceuticals such 
as the sulfonylurea class of drugs are able to directly stimulate insulin secretion via 
activation of the eponymous sulfonylurea receptor, and although sulfonylurea insulin 
secretagogue drugs are useful for treatment of T2DM their use is now deprecated due to 
concerns about β cell exhaustion [116, 117].  
Pancreatic β cells are not responsive to metabolic signals only; they are also capable 
of increasing insulin synthesis and secretion depending on endocrine, neuronal, and 
other stimuli [118, 119]. Growth and lactation hormones secreted into the blood of 
pregnant females cause β cell proliferation and an increase in insulin secretion [119], but 
other hormones also have insulin effects. The intestinal hormone glucagon-like peptide 1 
(GLP-1) directly stimulates the β cell to release insulin in response to a meal [120], and 
treatments that either extend the half-life of GLP-1 or provide a long-lasting GLP-1 
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homologue aid in glucose management for patients with T2DM [121]. Protein digestion 
promotes secretion of the stomach hormone gastrin which increases glucose stimulated 
insulin secretion, thereby enabling protein digestion to potentiate normal β cell response 
to post-prandial blood glucose elevations [122, 123]. Paracrine signaling within the islet 
also regulates β cell function; in humans paracrine release of acetylcholine by α cells 
primes the β cell for response to changes in blood glucose levels. In rodents α cells are 
not evenly distributed throughout the islet and therefore acetylcholine signaling to β cells 
is via a neuronal rather than paracrine mechanism [124]. Islet parasympathetic neurons 
are not the only relevant neurons to DM; the transient receptor potential vanilloid 
subfamily member 1 positive (TRPV1+) sensory neurons of the islet play a role in DM. 
TRPV1+ neurons are directly implicated in insulitis and autoimmune attack of β cells in 
T1DM, and for that reason islet TRPV1+ sensory neurons are being investigated as 
pharmacological targets for the prevention of T1DM [125, 126]. Beyond just glucose 
sensing, it is the interplay of metabolic, endocrine and neuronal factors that regulate β 
cell function and insulin secretion in response to nutrients and environment. 
 
I.C. The Endoplasmic Reticulum in the β Cell 
An individual β cell can synthesize one million insulin molecules per minute [127], 
and the accordant translational burden requires a well-developed endoplasmic reticulum 
(ER). The ER is the location of peptide synthesis and protein processing [128, 129], 
therefore the health of the ER is directly relevant to β cell function [130]. Significant 
disruption of β cell ER processes may activate intracellular stress signaling, leading to β 
cell apoptosis, diminished functional β cell mass, and eventually DM [131-133]. 
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I.C.1. Endoplasmic Reticulum Stress  
The specialized milieu of the ER lumen has specific requirements, and if these 
requirements are not met the result is ER stress [134]. ER stress in the pancreatic β cell 
has been established as a contributing factor to onset of both T1DM and T2DM [135, 
136]. The ER lumen contains specialized protein chaperones to guide the folding of 
nascent peptides as they are synthesized [137, 138]. Chaperones require that conditions 
in the ER meet certain pH, temperature and ionic requirements [139-142], and one such 
requirement is a Ca2+ concentration orders of magnitude higher than the cytoplasm 
[143]. as a consequence of impaired chaperone activity, misfolded proteins aggregate 
and cause stress within the ER [144]. 
In addition to insufficient Ca2+ concentration, potential causes of ER stress 
include inflammation, long chain saturated fatty acid surfeit, extreme levels of reactive 
oxygen species, drugs that inhibit ER function such as tunicamycin and thapsigargin, 
and mutations causing an accumulation of misfolded proteins [128, 145-147]. The result 
of ER stress is that unfolded and misfolded proteins cannot be trafficked to the Golgi 
apparatus for intracellular delivery or extracellular secretion, so these protein aggregates 
must be cleared from the ER by other means [134]. This ER stress related blockage in 
protein and peptide processing results in the activation of the intracellular unfolded 
protein response (UPR) [144, 148], leading to either cell recovery or death (Figure 2). 
 
I.C.2. Calcium in the β cell 
A key determinant of the β cell’s ability to fulfill its physiological role is strict 
regulation of ionic calcium [149-151]. When chronically overstimulated, Ca2+ 
homeostasis in the β cell is disrupted, and the internal stores of Ca2+ in the β cell are 
also affected [93, 152-155]. When ER Ca2+ concentration decreases calcium-dependent 
ER chaperone proteins such as calreticulin and calnexin are unable to perform their 
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Figure 2. Endoplasmic Reticulum Stress and the Unfolded Protein Response. 
When homeostasis of the ER is disrupted, unfolded proteins aggregate. The ER senses 
unfolded proteins and triggers ER stress response signaling pathways to respond to the 
accumulating stress. Early effects of ER stress response are adaptive, as the unfolded 
protein response (UPR) halts ordinary protein synthesis and increases the synthesis of 
ER stress resolution proteins. If the UPR is not able to resolve the stress, then apoptosis 
may be triggered via the internal apoptosis pathway [156]. 
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function. Under normal conditions these chaperone proteins facilitate the production of a 
higher quantity and quality of synthesized proteins, but without sufficient Ca2+, 
chaperone function is diminished [157]. Erosion of the steep Ca2+ concentration gradient 
between the ER lumen and cytosol therefore interferes with protein folding [136, 147, 
158, 159], and the stress due to sustained ER Ca2+ dysregulation can trigger β cell death 
[146, 160-162].  
Chronic hyperglycemia causes Ca2+ homeostasis disruption, dysregulation of 
intracellular signaling, derangement of peptide synthesis and impairment of β cell 
survival and function.  Other factors that contribute to the erosion of the ER Ca2+ 
gradient are inflammatory cytokines, hyperlipidemia, and excessive generation of 
reactive oxygen species [163-165]. 
 
I.C.3. The Unfolded Protein Response 
The unfolded protein response (UPR) is initially pro-survival as it attempts to resolve 
the cause of ER stress, but if the stress cannot be resolved the UPR can trigger 
apoptosis [128, 166]. When ER stress is initially detected, the cell responds by reducing 
the rate of transcription and translation to prevent the accumulation of additional toxic 
aggregates [134]. Not all peptides and protein synthesis is halted, however; the cell 
increases transcription and translation of proteins that aid in protein folding, protein 
trafficking, ER associated peptide degradation (ERAD), with the purpose of clearing the 
ER of harmful synthesis products [167]. If these attempts at recovery from ER stress fail, 
cells self-terminate by activating the C/EBP Homology Protein (CHOP) apoptosis 
pathway [145, 166]. 
Genetic studies in mouse models have informed critical components of the UPR in 
the β cell [168-170]. . If the UPR is not successful in resolving β cell ER stress, the result 
is loss of functional β cell mass and DM. One model illustrating the importance of the 
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UPR to β cell survival is a pancreas-specific knockout of Protein Kinase RNA-like 
Endoplasmic Reticulum Kinase (PERK). PERK maintains protein synthesis at a 
controlled rate, and pancreas-specific PERK knockout mice are prone to β cell ER 
stress, loss of functional β cell mass and DM [168]. Another mouse model unable to 
resolve ER stress also experience reduced functional β cell mass and DM, including 
CCAT-enhancer binding protein (C/EBP) transgenic mice, which also lose functional β 
cell mass due to irremediable ER stress [171]. Conversely, prevention of apoptosis due 
to ER stress via overexpression of the Apoptosis Repressor with Caspase Recruitment 
Domain (ARC) in the β cell maintains functional β cell mass and prevents DM [169]. A 
similar β cell survival advantage was also seen in the ER stress-resistant thioredoxin 
interacting protein (TXNIP) knockout mice [172]. Further studies of  similar β cell ER 
stress pathways have also provided evidence that unresolved ER stress causes β cell 
apoptosis, and that relieving β cell ER stress can prevent apoptosis and DM [131-133, 
139, 173].  
 
I.D. Sarco-endoplasmic reticulum ATPase 
Sarco-endoplasmic reticulum ATPases (SERCAs) are cellular calcium pumps 
responsible for maintaining the relatively high concentration of Ca2+ in the ER [174]. 
SERCA actively transports two calcium ions from the cytosol into the lumen of the ER 
per hydrolyzed ATP molecule (Figure 3) [175]. SERCA proteins are P-type ATPases 
with phosphorylation, calcium binding and nucleotide binding domains protruding from 
the cytosolic face of the ER membrane, and ten to eleven transmembrane loops creating 
a channel between the cytosol and the lumen of the ER [174, 176, 177]. SERCA is 
autophosphorylated at Aspartate-351 on the cytosolic face during the process of 
pumping calcium from the cytoplasm into the lumen of the ER, but this phosphorylation 
is understood to have only conformational effects [174, 176-178]. SERCA 
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Figure 3. Endoplasmic Reticulum Calcium Transporters. Transport proteins move 
Ca2+ ions across the ER membrane both into and out of the ER lumen. The inositol 
triphosphate receptor (Ins3PR) and the ryanodine receptor (RyR) allow Ca2+ to move 
down its concentration gradient from the ER lumen to the cytosol. The SERCA family of 
ion pumps hydrolyze one ATP molecule to move two Ca2+ ions into the lumen of the ER. 
The precise function of wolframin (Wfs1) is not known, but it is known to be an ER 
membrane protein required for Ca2+ reuptake from the cytosol to the lumen of the ER. 
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overexpression under basal conditions may cause dysfunction and cell death in cardiac 
myocytes [179-181], but if the overexpression is in the context of previously diminished 
SERCA or in states of stress then the effect is pro-survival [182, 183].  
There are multiple SERCA isoforms expressed in different tissues, with three 
isoforms expressed in the β cell [155]. Although the isoforms SERCA2a and SERCA3 
are also present, the most prevalent isoform is SERCA2b [155, 184]. SERCA3 has been 
observed to decrease under diabetic conditions, but loss of SERCA3 is not sufficient to 
cause DM in SERCA3 knockout animals [185, 186].  
 
I.D.1. Sarco-endoplasmic reticulum ATPase Isoform 2 (SERCA2) 
SERCA2 isoforms are expressed throughout the body but SERCA2 has been most 
studied in cardiac tissue, and a mouse model overexpressing SERCA2 demonstrated 
increased cardiac function in both normal and diabetic animals [187]. A mouse model 
with deleted SERCA2 in all tissues is embryonic lethal, however a whole-body SERCA2 
heterozygote mouse is viable [188]. These SERCA2 heterozygote mice demonstrate 
cardiac impairment, but the metabolic and potentially diabetic phenotype has not been 
extensively studied [189, 190]. Haploinsufficiency of SERCA2 in humans causes Darier’s 
disease, which manifests in skin rashes and lesions [191], but there has been little study 
of susceptibility to DM in Darier’s disease [192].  
There are two SERCA2 isoform subtypes: SERCA2a primarily found in cardiac and 
muscle tissue, and SERCA2b  which is expressed ubiquitously [193, 194]. The 
relevance of SERCA2a in the β cell has not been widely studied, but its comparatively 
low expression suggests that its function is less significant than the other two SERCA 
isoforms [155]. SERCA2b  is classified as a “slow-twitch” SERCA isoform in comparison 
to the “fast-twitch” SERCA1a and SERCA2a isoforms [195]. SERCA2b  has greater 
specificity for calcium transport than other SERCA isoforms, but it is also less 
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processive, which makes it ideal for maintaining a steep ER calcium gradient under 
normal cellular conditions [155, 185, 196].  
SERCA2b is also unique among SERCA isoforms in that it possesses an eleventh 
transmembrane loop and a regulatory C-terminus tail within the lumen of the ER [197], 
allowing its activity to be modulated by intraluminal ER signaling [198]. The eleventh 
transmembrane domain is responsible for the increased affinity of SERCA2b  for Ca2+ 
compared to other SERCA isoforms [199], whereas the intraluminal C-terminus allows 
isoform-specific regulation by factors within the lumen of the ER [177, 194, 200]. 
Decreased SERCA2b expression in the β cell is correlated with alterations in intracellular 
Ca2+ homeostasis, impaired insulin secretion, and cell death [201-203]. In fact direct 
interference with SERCA2 in the β cell can be fatal; the SERCA inhibitor thapsigargin is 
lethally toxic to β cells at millimolar concentrations, while SERCA2 interfering RNA 
causes irremediable ER stress due to calcium dysregulation [128, 147, 186, 203]. 
 
I.D.2. SERCA2 Regulation 
The regulation of SERCA2 is complex, incorporating regulation of transcription, rate 
of translation and post-translational modifications [174, 204], as well as interactions with 
other proteins and signaling pathways [179, 198, 205, 206]. ER stress initially leads to 
an increase in transcription of SERCA2 isoforms in cardiac and neuroendocrine cell 
types, however sustained ER stress or cytokine signaling results in SERCA2 
degradation [207-213].  This decrease does not eliminate SERCA2 expression entirely, 
but the concomitant ER Ca2+ dysregulation increases β cell vulnerability to apoptosis 
with further negative stimuli [155, 203]. 
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I.D.2.i. SERCA2 Transcriptional Regulation 
Knockdown of SERCA2 via interfering RNA causes translational upregulation of 
other Ca2+ pathways in response, which suggests an interconnection of Ca2+ sensing 
pathways and SERCA2 transcriptional regulation [214]. When vascular smooth muscle 
cells were treated in vitro with the irreversible SERCA inhibitor thapsigargin transcription 
and stability of multiple SERCA isoforms’ mRNA increased, but this increase in SERCA 
message was abrogated with Ca2+ chelation, suggesting once again that Ca2+ signaling 
is required to upregulate SERCA2 transcription in response to Ca2+ homeostasis 
disruption. The mechanism of this increase in SERCA2 transcription does not require: 
active synthesis of new proteins, calcineurin binding, protein kinase C (PKC) activity, 
Ca2+/calmodulin-dependent protein kinase (CAMK) activity or tyrosine kinase activity 
[215].  
Peroxisome proliferator activating receptor (PPAR) proteins also upregulate the 
transcription of SERCA isoforms in response to metabolic signaling, but the pathways 
and degree of enhancement varies by tissue. The pharmaceutical compound etoxomir 
increases SERCA2 transcription in cardiomyocytes, possibly via a mechanism involving 
the alpha isoform of PPAR (PPARα) [216], but in the β cell PPARα is not highly 
expressed [217]. PPAR isoform gamma (PPARγ) has also been shown to be a SERCA2 
transcriptional enhancer, and it is present in various cell types including the β cell [155, 
218, 219]. 
Hormones and growth factors can also signal increase in SERCA2 transcription 
however the mechanism by which each signal does so is isoform and tissue-specific. For 
example, thyroid hormone can signal skeletal- and cardio- myocytes to upregulate 
SERCA2 transcription [220, 221], while platelet-derived growth factor (PDGF) causes 
increased SERCA2 transcription in cardiomyocytes as well [222]. Estrogen and 
progesterone also enhance SERCA2 expression in cardiomyocytes and Sertoli cells, as 
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it has been observed that the lack of female hormones decreases SERCA2 transcription 
and protein levels [223-226]. Finally, and most importantly in the study of DM, insulin 
signaling via the insulin receptor affects SERCA2b expression and SERCA3 
transcription in the pancreatic β cell itself [227, 228].  
 
I.D.2.ii. SERCA2 Post-translational Regulation 
In cardiomyocytes and in pancreatic β cells, CaMK isoform II (CaMKII) 
phosphorylation of Serine-38 of SERCA2 increases its activity, thereby assisting in 
maintenance of the ER Ca2+ gradient [229, 230]. Unfortunately in situations of chronic 
Ca2+ stimulation, it has been observed in myocytes that the loss of phosphorylation by 
CAMKII also decreases SERCA2 activity [230-232]. 
In cardiomyocytes SERCA2 activity may also be inhibited by modifications due to 
reactive nitrogen species [233, 234]. SERCA2 is the most resistant SERCA isoform to 
peroxidization, and at low concentrations reactive oxygen species enhance SERCA2 
function [235, 236]. This enhancement is not unlimited, as the nitration of SERCA2 
residues Tyrosine-294 and 295 is correlated with decreased SERCA2 levels in skeletal 
muscle [174, 237-239]. When sulfonylation of Cysteine-674 accompanies these 
inhibitory nitrations, SERCA2 is further inhibited [240]. 
In addition to nitration and sulfonylation, in the presence of NO or other oxygen 
radicals Cysteines-498, 524, 613 and 674 become glutathionylated [174]. These 
glutathionylation modifications have been observed in vascular smooth muscle cells, and 
the modifications temporarily increase SERCA function in response to NO signaling. 
Under conditions of chronic stimulation, however, oxidation, of Cysteine-674 prevents 
this upregulation via glutathionylation [241, 242]. When PC12 pheochromocytoma cells 
are treated in vitro with EGTA to remove Ca2+, treated with DTT to inhibit disulfide bridge 
formation, or treated with tunicamycin to prevent glutathionylation, post-translational 
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modification by reactive oxygen and nitrogen species in a chronically oxidative 
environment impairs SERCA and calcium homeostasis [209]. In this way concentrations 
of reactive oxygen species that might be considered normal facilitate SERCA2 function, 
whereas higher concentrations of reactive oxygen species as seen with inflammation or 
chronic stimulation impairs SERCA2 function [243]. 
 
I.D.2.iii. SERCA2 Protein-Protein Interactions 
In addition to the signaling pathways that regulate SERCA2 via post-translational 
modifications, ER membrane and ER lumen proteins are able to influence the activity of 
SERCA2 via physical interactions. This intraluminal regulation is thought to occur 
especially in the presence of ER reactive oxygen species [244]. SERCA does not act 
independently; interactions with other proteins assist in the coordination of ER Ca2+ 
regulation. 
Proteins known to regulate SERCA2a activity in cardiomyocytes are sarcolipin and 
phospholamban, but they are not found in the pancreatic β cell [222]. The anti-apoptotic 
protein B-cell lymphoma 2 (Bcl-2) is embedded in the ER membrane and cooperates 
with SERCA2 to prevent apoptosis in the cardiomyocyte with Ca2+ dysregulation [174, 
222]. Calcium sensing proteins also affect SERCA2 function; the ER intraluminal protein 
calreticulin contributes to the adaptive glycosylation of the 11th transmembrane loop of 
SERCA2b [205], which modulates SERCA2b activity during Ca2+ oscillations. Like 
calreticulin, the chaperone proteins calnexin and ER protein 57 (GRP-58) also interact 
with luminal domains of SERCA2 to dampen extreme fluctuations in ER Ca2+ [198, 206].  
 
I.D.2.iv. Translational Regulation of SERCA2  
Little is known about the translation of SERCA2 from mRNA, and if there is 
translational regulation of SERCA2 it may vary by isoform or tissue type. When neuronal 
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cells were treated with thapsigargin and allowed to recover, there was a doubling of 
SERCA2b mRNA but levels of SERCA2b protein were unchanged [245]. In contrast, 
SERCA2a protein levels in skeletal muscle and in cardiomyocytes roughly equal 
SERCA2a mRNA levels [246]. Since the SERCA2b isoform dominates in the β cell, if 
one were to draw a conclusion from these limited studies it would be that an increase in 
SERCA2b mRNA does not necessarily result in an increase in SERCA2b protein levels, 
and that both protein and mRNA levels should be verified independently when possible.  
 
I.D.3. Summary of SERCA2  
Of the proteins in the SERCA family of Ca2+ pumps, the SERCA2 types are the most 
widely expressed throughout the body [187]. SERCA2b is the most highly expressed 
isoform in the β cell, followed by SERCA3 and SERCA2a, but it is SERCA2b that is 
required for normal ER Ca2+ homeostasis [155]. Without the steep ER Ca2+ gradient 
maintained by SERCA2b β cell function becomes impaired [186], and if the loss of 
functional β cell mass is sufficient the result is DM in the organism as a whole. 
 
I.E. Pancreatic and Duodenal Homeobox Protein 1 
Pancreatic and duodenal homeobox protein 1 (Pdx-1), previously referred to in the 
literature as IPF-1, IUF-1, IDX-1, STF-1 and GSF, was discovered by multiple 
investigators at approximately the same time, though each group described separate 
functions for this transcription factor [247, 248]. In vertebrates Pdx-1 is required for 
embryonic development of the pancreas [249], and in combination with the homeobox 
protein NK6 Homeobox protein 1 (Nkx6.1) Pdx-1 is also the defining transcription factor 
of the β cell [250, 251]. Pdx-1 regulates several key aspects of β cell function, including 
sensing of blood glucose, mitochondrial function, ER health, insulin synthesis and insulin 
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secretion [252-258]. In addition to the β cell Pdx-1 is expressed in islet δ cells and in 
select regions of the hypothalamus [259].  
 
I.E.1. Pdx-1 and Pancreatic Organogenesis 
Pdx-1 expression begins in utero in the foregut of the mouse at day 8.5, and this 
expression results in the separation and differentiation of the embryonic pancreas. Pdx-1 
is then expressed in all cells of the pancreas until embryonic day 9.5, when pan-
pancreatic Pdx-1 expression ceases [248]. As of embryonic day 13 and until the end of 
life, Pdx-1 is thereafter expressed primarily in β cells [259].  
Lack of functional Pdx-1 results in pancreatic agenesis in mice and it is lethal shortly 
after birth [260, 261]. Haploinsufficiency of Pdx-1 in humans causes Maturity Onset 
Diabetes of the Young 4 (MODY4), but this condition is extremely rare [262, 263]. 
Homozygous deletion of Pdx-1 results in human pancreatic agenesis, and only two 
confirmed cases have been observed [260, 261, 264, 265]. 
 
I.E.2. Pdx-1 and β Cell Identity 
Pdx-1 is essential to both pancreatic development and β cell maturation [71, 262]. 
Along with other transcription factors Pdx-1 regulates v-Maf avian musculoaponeurotic 
fibroscarcoma oncogene homolog A (MafA), which contributes to the unique epigenetic 
signature of the β cell [266, 267]. Pdx-1 is also critical to mature β cells where it 
enhances transcription of proteins essential to β cell function and proliferation [248]. The 
transcriptional targets of Pdx-1 include glucose transporter 2 (GLUT2) [258], glucokinase 
[252], insulin genes 1 and 2 (INS1, INS2) [253, 254], homeobox factor Nkx6.1 [268], 
nuclear-encoded mitochondrial factor A (TFAM) [257], as well as other proteins 
important to glucose sensing, insulin synthesis, insulin secretion and β cell survival 
[269]. Pdx-1 expression is also required for β cell proliferation [248, 270], and without 
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Pdx-1 compensatory glucose-stimulated β cell hyperplasia is impaired [271]. Equally 
important to its other roles, Pdx-1 also regulates the expression of ER stress related 
proteins activating transcription factor 4 (Atf4) [255], and Wfs1 [256]. 
 
I.E.3. Pdx-1 Regulation 
The regulation of Pdx-1 is complex with many different factors affecting its 
transcription, activity or degradation [248]. Pdx-1 activity tends to be increased by 
glucose signaling, insulin stimulation, and short-term cellular stress, whereas chronic β 
cell stress leads to decreased Pdx-1 levels [248, 272-274]. 
 
I.E.3.i. Regulation of Pdx-1 Transcription 
The Pdx-1 protein is encoded by the Ipf1 gene, and the Ipf1 promoter has binding 
sites for multiple types of DNA binding motifs, thus protein complexes rather than 
individual transcription factors are required to enhance Pdx-1 transcription [248]. During 
development and β cell differentiation the complexes of transcription factors that 
enhance Pdx-1 transcription include: hepatic nucleocyte factors 3 beta and 1 alpha 
(HNF-3β, HNF-1α) [275, 276], NeuroD (also called β2) [277], upstream stimulatory factor 
(USF) [278], PPARγ [251], and transcription factor specificity protein 1 (SP1) [279]. HNF-
3β is of particular interest because it is itself transcriptionally upregulated by Pdx-1, thus 
forming a positive feedback loop, as levels of both transcription factors are positively 
correlated [280]. The propagation of extracellular signaling to the nucleus results in 
either enhanced transcription of Pdx-1 to increase protein levels or prevention of Pdx-1 
degradation [281, 282]. 
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 Figure 4. Pdx-1 transcription target proteins. Pdx-1 enhances transcription of 
proteins involved with every facet of β cell function.  Targets that affect glucose sensing 
include glucose transporter 2 (GLUT2) and glucokinase (GCK). Pdx-1 increases the 
synthesis of proteins intended for secretion outside of the cell including insulin (INS1) 
and amylin (IAPP), while Pdx-1 also enhances the mitochondrial transcription factor A 
(TFAM) which helps the mitochondria trigger secretion via ATP synthesis. In addition, 
Pdx-1 enhances transcription of proteins that prevent maladaptive ER stress including 
Wfs1 and Atf4. 
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I.E.3.ii. Regulation of Pdx-1 Activity 
Pdx-1 is post-transcriptionally modified in order to affect either its activity or its 
intracellular localization. Pdx-1 activity is upregulated by conditions that call for an 
increase in insulin synthesis, and factors that upregulate Pdx-1 activity include: p38 MAP 
kinase (p38) [281], phosphoinositide 3 kinase (PI3K) [272], stress-activated protein 
kinase 2 (SAPK2) [283], atypical protein kinase C zeta (PKCζ) [284], and follistatin [285]. 
These proteins cause an activating phosphorylation of Pdx-1, thereby enhancing its 
ability to bind to target gene promoters [248, 286].  
It is not only intracellular signaling that increases the effect of Pdx-1 in the β cell; 
hormones and metabolic signaling also play a role. Basic Fibroblast Growth Factor 
(bFGF) [287], triiodothyronine (T3), heparin-binding EGF-like growth factor (HB-EGF) 
[274], insulin [288], TNFα and GLP-1 signaling increase Pdx-1 transcription [274]. 
Nutrients and vitamins that upregulate Pdx-1 transcription in the islet include biotin [289] 
and nicotinamide [287], while glucose increases Pdx-1 activity by causing its 
phosphorylation via the p38 mitogen-activated protein kinase pathway [248, 283]. The 
fact that many of the hormonal factors that enhance Pdx-1 transcription and therefore 
contribute to β cell proliferation are growth factors is logical, inasmuch as β cell mass 
has a positive correlation to body mass in general [80]. Contrariwise, glucocorticoids 
interfere with Pdx-1 transcription by negatively affecting HNF-3β and thereby reducing 
Pdx-1 transcription [248], so not all humoral signaling serves to increase Pdx-1 levels or 
activity in the β cell. 
 
I.E.3.iii. Regulation of Pdx-1 Nuclear Localization 
As a transcription factor, Pdx-1 must be in the nucleus to affect cellular function. Pdx-
1 has a well-characterized nuclear location signal RRMKWWK [282], and the small 
GTPase protein Ran insures that Pdx-1 remains in the nucleus so long as the nuclear 
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localization signal is accessible [290]. Shuttling Pdx-1 out of the nucleus effectively 
silences it, and indeed when Pdx-1 is located in the cytosol it is degraded by the 
proteosome [291, 292]. Oxidative and inflammatory stress in the β cell causes activation 
of the c-Jun N-terminal kinase (JNK) pathway, which in turn leads to an inactivating 
phosphorylation of Pdx-1 and subsequent nuclear export [293]. The propagation of 
extracellular signaling to the nucleus results in either enhanced transcription of Pdx-1 or 
in the prevention of Pdx-1 degradation, both leading to an increase in Pdx-1 protein 
levels [281, 282]. 
 
I.E.4. Pdx-1 and β Cell Stress 
Under oxidative stress, glycotoxic and inflammatory conditions of the diabetic milieu 
the expression of Pdx-1 is impaired and Pdx-1 levels decrease [294, 295]. When Pdx-1 
levels decrease, β cell ER stress increases, which triggers the UPR [170]. Initially the 
UPR is adaptive, as the decrease in insulin synthesis burden putatively allows a 
stressed β cell to recover [156], but in the chronic condition the loss of Pdx-1 leads to 
loss of functional β cell mass, and under these circumstances the loss of Pdx-1 adds 
functional insult to cellular injury [136, 295]. 
By downregulating Pdx-1 the chronically stressed β cell forfeits the ability to 
proliferate [296]. Eventually failure to manage the β cell population occurs by cell death 
along with lack of proliferation, and the glycemic load worsens for β cells that still 
function, creating a vicious cycle of dysfunction and death [297, 298]. 
 
I.F. Peroxisome Proliferator-Activated Receptor γ 
PPARγ is a type 2 ligand-dependent nuclear receptor present in the β cell, and it is 
the drug target of the thiazolidinedione (TZD) class of pharmaceuticals [299]. PPARγ is 
often complexed with the retinoid X receptor transcription factor (RXR) when active, and 
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although PPARγ is best known for its effects in adipocytes and hepatocytes [300, 301], 
the role of PPARγ in β cell function is highly significant [302, 303].  
 
I.F.1. PPARγ Regulation 
Although increasing the expression of PPARγ is one way of increasing its activity 
[304], PPARγ activity is also regulated by post-translational modification [305]. 
Phosphorylation of PPARγ at Serine-273 via cyclin-dependent kinase 5 (CDK5) does not 
prevent PPARγ from binding to the PPAR response element (PPRE), but it does prevent 
PPARγ enhancement of target gene transcription [306, 307]. The mechanism of this 
inhibition via phosphorylation at Serine-273 of PPARγ is unknown, but one possible 
explanation is that the added phosphate group prevents binding of PPARγ co-factors 
due to steric or electrostatic interference.  
 
I.F.2. PPARγ Function in the β Cell 
In order to promote transcription of target genes, PPARγ requires ligands to complex 
with it, particularly RXR [308, 309]. The structure of PPARγ includes a large binding 
pocket which could accommodate a variety of cofactors [310, 311], and proteins it is 
known to interact include those in lipid-related signaling pathways like C/EBP, sterol 
regulatory element binding protein 1, PPAR co-activator 1, and hepatic nuclear factor 4 
[312]. Additional ligands found to complex with PPARγ include transcription factor 
complex-forming proteins such as steroid receptor co-activating factor 1,  Creb-binding 
protein, E1A binding protein p300 , as well as fatty acids, prostanoid 15-deoxyΔ12,14PG 
J2, prostaglandins, leukotrienes and eicosanoid molecules [300, 310, 313, 314]. The 
binding of cofactors increases PPARγ activity and provides specificity to PPARγ 
transcriptional enhancement. 
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PPARγ is widely distributed in many tissue types throughout the body, but its role in 
the β cell is related to β cell function and identity [217, 251, 315]. PPARγ in the β cell 
also maintains euchromatin structure and plays a role in the mitigation of ER stress 
[303]. Under normal metabolic conditions PPARγ inhibits β cell proliferation in favor of 
maturation, however when fed high fat diet or after partial pancreatectomy PPARγ 
enhances proliferation by upregulating Pdx-1 and Nkx6.1 [251, 316].  
In the β cell PPARγ increases the transcription and expression of Pdx-1, Nkx6.1, 
GCK and GLUT2 after partial pancreatectomy [251]. PPARγ also decreases the 
expression of cytokines and the inflammatory nuclear factor kappa-light-chain-enhancer 
of activated Β cells (NFκB), thereby promoting cell survival and function [146, 314, 317]. 
PPARγ contributes to ER Ca2+ homeostasis by increasing SERCA2 transcription [201]. 
Levels of PPARγ are not decreased under conditions of diabetic stress in the β cell; 
indeed PPARγ  levels have been seen to increase in the β cell when exposed to the 
diabetic milieu [93]. of particular interest in the present work is the binding of PPARγ to 
the SERCA2 promoter [155]. 
With hyperglycemia, CDK5 phosphorylates PPARγ at Serine-273 and inhibits 
PPARγ-mediated transcriptional effects.  Interestingly this post-translational modification 
does not impact binding of PPARγ to a gene promoter [318]. 
 
I.F.3. PPARγ Pharmaceuticals 
The TZD drug pioglitazone maintains the activity of PPARγ both by inhibiting 
phosphorylation of Serine-273 by CDK5 as well as forming a direct complex with PPARγ 
[155, 300, 306, 319]. Pioglitazone is a second generation TZD most often prescribed in 
combination with other pharmaceuticals to aid in managing hyperglycemia with T2DM 
[320, 321]. The primary mechanism of action for the TZD class of drugs for glycemic 
control has until now been thought to be insulin sensitization of adipose tissues via its 
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dual agonism of PPARα and PPARγ [319], but data published by this laboratory as well 
as others have demonstrated that TZD drugs also have beneficial effects in the β cell 
itself [155, 322, 323]. 
Since their introduction different TZD drugs have come under scrutiny for various 
safety concerns. Troglitazone was the first TZD removed from the market for concerns 
over hepatotoxicity [300]. Second-generation TZD drugs did not show evidence of 
hepatotoxicity [324], however a new concern regarding possible cardiac side effects with 
rosiglitazone arose [325, 326]. Rosiglitazone remains available in the U.S. despite an 
increased risk of myocardial infarction [327], as does pioglitazone despite an association 
with bladder cancer [328], although both drug types carry FDA warning labels [329]. 
 
I.G. Forkhead Box Protein O1 in the β Cell 
Forkhead box protein O1 (FOXO1) is a transcription factor that enhances expression 
of genes related to fuel production and storage [330]. FOXO1 is found in multiple tissue 
types however its effects in the hepatocyte, adipocyte and pancreatic β cell are most 
relevant to the study of DM. In the β cell FOXO1 is noted as a pro-survival and pro-
differentiation factor but counterintuitively also as a particularly potent antagonist of Pdx-
1 [331]. 
FOXO1 has long been considered the opposite of Pdx-1 in the β cell, and except that 
both proteins promote β cell survival the two are mutual antagonists [332]. Insulin 
signaling inhibits FOXO1 by the protein kinase B pathway, which maintains FOXO1 
localization in the cytoplasm away from its target genes in the nucleus [333]. Oxidative 
and inflammatory stress in the β cell causes activation of the JNK pathway and FOXO1, 
leading to downstream inactivating phosphorylation of Pdx-1 and Pdx-1 nuclear export 
[293]. FOXO1 further inhibits the transcription of Pdx-1 by interfering with Hnf-3β and 
PPARγ enhancement of IPF1 transcription [334, 335]. Reduction in Pdx-1 levels inhibits 
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β cell proliferation, so while FOXO1 improves individual β cell survival it impairs overall 
functional β cell mass [336].  
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Chapter II. Results 
II.A. Pdx-1 and SERCA2b Levels Decrease Under Diabetic Stress 
Pdx-1 levels decrease under hyperglycemic and inflammatory conditions, as in the 
diabetic milieu of the β cell [248]. SERCA2b levels also decrease in the β cell under 
diabetic conditions [155], so it was our goal to test whether alterations in Pdx-1 and 
SERCA2b expression in the β cell were correlated. Immunoblot and quantitative PCR 
were used to measure β cell Pdx-1 and SERCA2 expression in cell culture and in islets 
isolated from mouse models of DM and cadaveric human donors with and without 
T2DM. 
 
II.A.1. Pdx-1 and SERCA2b Levels in the db/db Diabetic Mouse Model 
Our previous work has shown significantly decreased expression of SERCA2b 
mRNA and SERCA2 protein in islets isolated from C57BLKs/J-db/db (db/db) mice [144, 
155].  To investigate the potential correlation between Pdx-1 and SERCA2b expression 
in the β cell in diabetic animals, islets were isolated from 12-week-old db/db mice and 
heterozygote littermate controls. In a preliminary experiment, Pdx-1 and SERCA2b 
protein were decreased in db/db islets compared to controls (Figure 5A). Similar 
findings were observed measuring Pdx-1 and SERCA2b mRNA levels (Figure 5B). 
 
II.A.2. Pdx-1 and SERCA2b Levels in Cadaveric Diabetic Human Islets 
Next, mRNA was isolated from cadaveric islets from donors with Type 2 diabetics 
and donors without diabetes. Donors with a history of T2DM showed decreased average 
mRNA of both Pdx-1 and SERCA2b (Figure 6A). Levels of SERCA2b and Pdx-1 mRNA 
were graphed as a line with the X-coordinate corresponding to SERCA2b mRNA and the 
Y-coordinate corresponding to Pdx-1 mRNA. A significant linear relationship was 
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Figure 5. Pdx-1 and SERCA2b levels are decreased in db/db mice compared to 
db+ littermate controls. Protein and RNA were isolated from 12-week old db/db and 
db+ control mouse islets for measurement of relative Pdx-1 and SERCA2b expression. 
A) Protein immunoblot was performed using antibodies against SERCA2, Pdx-1, and 
actin loading control. B) Reverse-transcribed RNA was subjected to real-time PCR for 
quantification of SERCA2b and Pdx-1 transcript levels. Indicated comparisons are 
significantly different (**p < 0.01) by multiple t-test with Sidak-Bonferroni post-test 
correction. Panel A, islets from 3 db/db and 3 db+ mice were pooled, with 100 pooled 
islets per lane displayed as a representative immunoblot. Panel B, pooled islets from 3 
db/db and 3 db+ mice were used for quantitative PCR, with 7 db+ and 9 db/db qPCR 
samples total. Results are displayed as the means ± S.E.M. 
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Figure 6. Pdx-1 and SERCA2b expression levels are correlated in cadaveric 
human donor islets. Human islets from diabetic and non-diabetic human donors were 
lysed and mRNA levels for Pdx-1 and SERCA2b were measured via quantitative PCR. 
A) Pdx-1 and SERCA2b mRNA levels were graphed as points on the Y-axis and X-axis 
with the Best-fit line calculated from the qPCR results. Islets isolated from 4 males, 4 
females; 3 T2DM and 5 non-DM; average age 48 years and average BMI 26. Indicated 
positive correlation is significant (p < 0.05) as calculated by Best-fit analysis. 
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observed with a slope (m) of 2.760 ± 1.044 and a coefficient of determination (R2) value 
of 0.5380, suggesting that mRNA expression levels of Pdx-1 and SERCA2b in human 
islets are positively correlated (Figure 6A). 
 
II.A.3. Pdx-1 and SERCA2b Levels in an In Vitro Model of Diabetes Mellitus 
Previous work has demonstrated a decrease in SERCA2b expression using an in 
vitro model to mimic the pro-inflammatory milieu of diabetes [155]. INS-1 832/13 rat 
insulinoma cells were treated with 25 mM glucose (high glucose, or HG) combined with 
5 ng/ml of interleukin-1β (IL-1β) for 16 and 24 hours, after which protein and mRNA 
levels of Pdx-1 and SERCA2b were measured.  At 16 hours post HG+IL-1β treatment, 
decreased Pdx-1 and SERCA2b protein levels were observed, with a representative blot 
and quantification shown. The results of 24 hours of HG+IL-1β were not significantly 
different from results observed at 16 hours (Figure 7A-B).  
Differences in mRNA expression were also measured at 16 and 24 hours. At 16 
hours HG+ IL-1β treatment Pdx-1 mRNA decreased to 50% expression, whereas 
SERCA2b mRNA did not significantly decrease, but after 24 hours of HG+IL-1b stress 
SERCA2b mRNA also decreased to approximately 50% of untreated levels (Figure 7C).   
Because the insulin gene is a known transcriptional target of Pdx-1 [337], 
quantification of pre-insulin mRNA was measured to confirm a loss of transcriptional 
enhancement by Pdx-1 with HG+IL-1b stress.  Decreased pre-insulin mRNA expression 
was observed in correlation with decreased Pdx-1 (Figure 7D). In contrast, 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is not a Pdx-1 target [338], 
therefore GAPDH mRNA was measured to investigate whether non-Pdx-1 target 
proteins had a similar correlation to pre-insulin and SERCA2b. No significant change in 
GAPDH expression was observed with HG+IL-1β treatment (Figure 7D). 
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Figure 7. Levels of Pdx-1 and SERCA2b protein and mRNA are decreased in an in 
vitro model of the diabetic milieu. INS-1 832/13 rat insulinoma cells were treated with 
25 mM glucose and 5 ng/ml IL-1β (HG+IL-1β) for 16 and 24 hours. A-B) Immunoblot was 
performed using antibodies against SERCA2, Pdx-1, and actin. Quantitative protein 
levels are shown graphically. C-D) Reverse-transcribed RNA was subjected to real-time 
PCR for quantification of SERCA2b, Pdx-1, pre-insulin, and GAPDH transcript levels. 
Indicated comparisons are significantly different (*p < 0.05, **p < 0.01) or not statistically 
significant (n.s.p > 0.05), by ANOVA with multiple comparisons. n=4 or more in all panels. 
Results are displayed as the means ± S.E.M. 
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II.B. Knockdown of Pdx-1 Causes Intracellular Calcium Dysregulation 
Our results demonstrate that decreased Pdx-1 and SERCA2b expression under 
diabetic conditions are correlated, but evidence of a direct relationship was lacking. In 
order to ascertain if the loss of Pdx-1 was causally related to diminished SERCA2b in 
the β cell, an in vitro strategy of Pdx-1 small interfering RNA was undertaken. 
 
II.B.1. Knockdown of Pdx-1 Decreases SERCA2b Protein and mRNA 
Adenoviral siRNA-mediated knockdown of Pdx-1 was performed in INS-1 832/13 
cells, which express Pdx-1 at high levels under normal conditions [339, 340]. In the INS-
1 cells treated with siRNA adenovirus, Pdx-1 levels were reduced by approximately 
90%, resulting in a 50% decrease in SERCA2b protein (Figure 8A-B). 
Levels of SERCA2b mRNA transcript after Pdx-1 knockdown were quantified, and 
with an approximately 90% Pdx-1 decrease in mRNA, there was an approximate 
decrease of 60% in SERCA2b mRNA. There was no significant decrease in SERCA2b 
mRNA expression with a random sequence siRNA adenovirus (Figure 8C).  Taken 
together, these protein and mRNA results demonstrate that β cell SERCA2b levels are 
decreased with small interfering RNA knockdown of Pdx-1.  
 
II.B.2. Knockdown of Pdx-1 Changes the Ratio of Cytosolic/ER Ca2+ 
Loss of Pdx-1 alters β cell Ca2+ compartmentalization leads to decreased ER Ca2+ 
and increased cytosolic Ca2+ levels, consistent with a loss of mediated Ca2+ influx into 
the lumen of the ER. INS-1 cells were transduced with siPdx-1 adenovirus or control 
siRNA then incubated with Fura 2-AM Ca2+ dye to measure cytosolic Ca2+ levels. The 
ratio of 340/380 wavelength excitation is correlated with cytoplasmic Ca2+ concentration, 
and this ratio showed that Pdx-1 knockdown significantly increased Ca2+ levels within the 
cytosolic compartment (Figure 9). 
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Figure 8. Pdx-1 siRNA in INS-1 cultured cells. INS-1 832/13 rat insulinoma cells were 
transduced with an adenovirus that expressed siRNA against Pdx-1. A-B) Immunoblot 
was performed using antibodies against SERCA2, Pdx-1, and actin. Quantitative protein 
levels are shown graphically. C) RNA was subjected to real-time PCR for quantification 
of SERCA2b and Pdx-1 transcript levels. Indicated comparisons are significantly 
different (*p < 0.05, **p < 0.01) by one-way ANOVA with multiple comparisons. n=4 or 
more. Results are displayed as the means ± S.E.M. 
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Figure 9. Cytoplasmic Ca2+ measurement with Pdx-1 siRNA using Fura-2AM 
fluorescent dye. The Fura 2-AM 340/380 fluorescence ratio was measured as 
described in the Experimental Procedures, in untreated INS-1 cells and in INS-1 cells 
transduced with siPdx-1 or random siRNA adenovirus. Indicated comparisons are 
significantly different (**p < 0.01) by ANOVA with multiple comparisons. n=at least 3 
random fields, with at least 20 cells per field. Results are displayed as the means ± 
S.E.M. 
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II.B.3. Knockdown of Pdx-1 Decreases the Concentration of ER Ca2+ 
To assess the impact of Pdx-1 loss on ER Ca2+ levels, INS-1 cells were transduced 
with an ER-targeted D4ER adenovirus in parallel with a siPdx-1 or random siRNA 
adenovirus. Fluorescence lifetime imaging microscopy (FLIM) was performed as outlined 
in the Experimental Procedures  [341]. Using this strategy, an increase in the lifetime of 
the enhanced cyan-fluorescent protein (ECFP) donor indicates less FRET efficiency and 
therefore lower ER Ca2+. 
Random fields were imaged in each dish with each treatment condition. 
Representative micrographs of transduction with either random siRNA or siPdx-1 
adenovirus provide visual representation of the functional consequence Pdx-1 
knockdown (Figure 10A). When fluorescence lifetime was quantified, ECFP donor 
lifetime increased significantly from 1.72 ± 0.0213 ns with random siRNA to 1.83 ± 
0.0214 ns with siPdx-1, consistent with reduced ER Ca2+ with Pdx-1 knockdown (Figure 
10B).  
 
II.C. Pdx-1 Enhances Transcription at the SERCA2 Promoter 
Pdx-1 is known to bind to TA-rich regions including TAAT, ATTA and TAAAT 
sequences in the promoters of target genes [342, 343]. The SERCA2 promoter has 
multiple putative Pdx-1 binding sites, and so we investigated whether exogenous Pdx-1 
supplementation increased activity at the SERCA2 promoter. 
 
II.C.1. Pdx-1 Overexpression in Fibroblasts Increases SERCA2b 
NIH-3T3 mouse fibroblast cells express SERCA2b but do not natively express Pdx-1.  
To test the relationship between Pdx-1 and SERCA2b expression directly, NIH-3T3 
fibroblasts were transduced with Pdx-1 adenovirus which resulted in an approximate 
 
42 
 
 B
A
R a n d o m
s iR N A
P d x -1  
s iR N A
1 .6
1 .7
1 .8
1 .9
2 .0
F
lu
o
re
sc
e
n
ce
 L
ife
tim
e
 (
n
s)
* *
n
a
n
o
se
co
n
d
s
P d x -1
s iR N A
R a n d o m
s iR N A
1 .6
1 .8
2 .0
2 .2
2 .4
2 .6
2 .8
2 0 µ M2 0 µ M
 
Figure 10. Direct measurement of ER Ca2+ using an ER-targeted D4 fluorescent 
protein. INS-1 cells were transduced with a D4ER Ca2+ reporter adenovirus in 
combination with adenovirus expressing siPdx-1 and endoplasmic reticulum Ca2+ was 
measured using Fluorescence Lifetime Imaging Microscopy (FLIM). A) Representative 
FLIM micrograph. B) Quantification of FLIM measurements. Indicated comparisons are 
significantly different (**p < 0.01) by Student’s t-test.  Results are displayed as the 
means ± S.E.M. 
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two-fold increase in SERCA2 protein levels (Figure 11A-B). Quantitative PCR also 
showed an increase in SERCA2b mRNA with exogenous Pdx-1 transduction (Figure 
11C). 
 
II.C.2. Pdx-1 Transduction Increases Transcription of a SERCA2 Luciferase 
Construct 
In silico analysis demonstrated five putative Pdx-1 binding elements in the SERCA2 
promoter (Figure 12A). To determine if Pdx-1 was a transcriptional enhancer of the 
SERCA2 gene, reporter assays were undertaken using different lengths of the human 
promoter fused to a luciferase coding gene. NIH-3T3 cells were co-transfected with 
SERCA2 luciferase constructs and human Pdx-1 plasmid. Luciferase activity was 
measured 24 hours after transfection and normalized to total protein content. Co-
transfection of Pdx-1 increased luciferase expression 3-4 fold over empty vector control 
in all constructs tested (Figure 12B). There were no significant differences between any 
of the constructs that were co-transfected with Pdx-1. 
 
II.C.3. Pdx-1 Transduction Increases Transcription of a SERCA2 Luciferase 
Construct 
All of the constructs included the most proximal putative site, so this suggested that 
the binding region closest to the transcriptional start site may be a key regulatory region 
for Pdx-1-mediated transcriptional enhancement of the SERCA2 gene. This region of the 
SERCA2 promoter maintains close homology between several species of mammals 
including human, mouse, and rat, and since it was a likely site for Pdx-1 binding, 
deletion-mutation of the proximal putative Pdx-1 element was undertaken (Figure 13A). 
Eight base pairs were deleted from the shortest length construct and no increase in  
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Figure 11. The effect of exogenous Pdx-1 overexpression on SERCA2b levels in 
NIH-3T3 cells. Pdx-1 was overexpressed via adenoviral transduction in NIH-3T3 mouse 
fibroblast cells that lack native expression of Pdx-1. A-B) Immunoblot was performed 
using antibodies against SERCA2, Pdx-1, and actin. A) Representative blot of Pdx-1 
overexpression in NIH-3T3 cells. B) Quantification of immunoblot experiments. C) RNA 
was subjected to real-time PCR for quantification of SERCA2b transcript levels.  
Indicated comparisons are significantly different (*p < 0.05, **p < 0.01) by ANOVA with 
multiple comparisons. n=6 or greater. Results are displayed as the means ± S.E.M. 
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Figure 12. Co-transfection of Pdx-1 with SERCA2 promoter luciferase constructs. 
Four constructs consisting of the human SERCA2 promoter placed upstream of a 
luciferase coding region were transfected into NIH-3T3 mouse fibroblast cells. Luciferase 
activity was assayed comparing the results of Pdx-1 co-transfection to transfection with 
an empty vector control. A) Five putative Pdx-1 binding regions were identified in the 
human SERCA2 promoter, each region containing between one and three potential 
binding sites. B) Results of co-transfection with Pdx-1 or with control for each SERCA2 
promoter construct. Indicated comparisons are significantly different (**p < 0.01) by 
multiple t-test with Sidak-Bonferroni post-test. n=10 or greater. Results are displayed as 
the means ± S.E.M. 
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luciferase activity was observed when co-transfecting Pdx-1 with this mutant construct 
(Figure 13B). 
 
II.C.4. Pdx-1 Chromatin Immunoprecipitation of the SERCA2 Promoter 
For in vivo confirmation of direct Pdx-1 binding to the proximal Pdx-1 promoter 
region, chromatin immunoprecipitation (ChIP) experiments were performed using whole 
cell extract isolated from INS-1 cells. Results showed a 2-fold increase in recovery of the 
proximal SERCA2 promoter following immunoprecipitation with anti-Pdx-1 antibody, and 
the confirmed Pdx-1 element of INS1 promoter [337] was also enriched in the Pdx-1 
immunoprecipitated sample (Figure 14A). The actin gene ACTB is not a target of Pdx-1 
transcriptional enhancement, and it was not enriched in the immunoprecipitated sample, 
confirming that the pulldown of SERCA2 and INS1 promoter regions was not a 
generalized effect applicable to non-targets of Pdx-1 (Figure 14B).  
 
II.D. Pdx-1 Haploinsufficient Mice Have Decreased Levels of SERCA2b 
Complete knockout of Pdx-1 is perinatal lethal in mouse models, therefore Pdx-1 
haploinsufficient mice were used to study the relationship between Pdx-1 and SERCA2b 
in vivo [344]. Mice were fed either a normal chow diet (17% of calories from fat) or a high 
fat diet (45% of calories from fat). The high fat diet was chosen to replicate the finding of 
Sachdeva et al. that islets from Pdx-1 haploinsufficient mice on high fat diet 
demonstrated ER stress [170]. 
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Figure 13. SERCA2 promoter luciferase construct with mutated proximal 
putative Pdx-1 binding element. To determine whether Pdx-1 enhanced SERCA2 
transcription at this site the proximal putative Pdx-1 was deleted and luciferase activity 
measured. A) Homology between human, rat, and mouse promoters is indicated. B) 
NIH-3T3 cells were co-transfected with wild-type or mutated SERCA2 promoter and 
luciferase constructs combined with Pdx-1 plasmid or empty vector control. Indicated 
comparisons are either significantly different (**p < 0.01) or not significantly different (n.s.p 
> 0.05) by multiple t-test with Sidak-Bonferroni post-test. n=5 or greater. Results are 
displayed as the means ± S.E.M. 
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 Figure 14. Pdx-1 directly binds the proximal SERCA2 promoter. INS-1 cells were 
harvested and subjected to chromatin immunoprecipitation (ChIP) analysis. Quantitative 
PCR was used to measure recovery of the SERCA2 or INS1 promoters following 
immunoprecipitation with anti-Pdx-1 antibody or normal rabbit IgG. A) Pulldown of the 
proximal putative Pdx-1 binding element in the SERCA2 promoter and a confirmed Pdx-
1 binding site in the INS1 promoter region. Results are expressed as fold-increase in 
percent recovery of the target gene compared to rabbit IgG. B) Comparison of the Pdx-1 
non-target ACTB promoter region between Pdx-1 antibody and normal rabbit IgG as 
compared to signal from the immunoprecipitation input sample. Results are expressed 
as fold-increase in percent recovery of the target gene compared to ACTB signal in the 
input sample. Indicated comparisons are significantly different (*p < 0.05) or not 
significantly different (n.s.p > 0.05) by t-test, or by multiple t-test with Sidak-Bonferroni 
post-test. n=4 or greater. Results are displayed as the means ± S.E.M. 
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II.D.1. Pdx-1 Haploinsufficient Mice Fed Normal Chow Diet 
Pdx-1 haploinsufficient mice and wild-type littermates were fed a normal chow diet 
containing 17% of calories from fat.  At 11 weeks of age, intraperitoneal glucose 
tolerance tests (IPGTT) were performed.  As previously observed by other groups, Pdx-1 
haploinsufficient mice were glucose intolerant compared to wild type littermates (Figure 
15A-B) [170, 271, 345, 346]. Although the Pdx-1 haploinsufficient mice were not frankly 
diabetic, SERCA2b protein and mRNA were significantly decreased in islets isolated 
from Pdx-1 haploinsufficient mice compared to wild type littermates (Figure 15C-E). 
 
II.D.3. Pdx-1 Haploinsufficient Mice Fed High Fat Diet SERCA2b Expression 
Pdx-1 haploinsufficient mice were fed a high-fat diet containing 45% calories from fat 
for 8 weeks, after which islets from Pdx-1 haploinsufficient and wild-type mice were 
isolated. Immunoblot analysis revealed that Pdx-1 and SERCA2 protein levels were 
decreased (Figure 16A-B). Isolated islets also showed a decrease in Pdx-1 and 
SERCA2b mRNA expression (Figure 16C). The X-box binding protein 1 (Xbp1) mRNA 
transcript becomes spliced to an active form when the β cell undergoes ER stress, and 
so both spliced and unspliced Xbp1 mRNA levels were measured in isolated islets. The 
ratio of spliced-to-unspliced Xbp1 was significantly higher in the islets of Pdx-1+/- mice 
fed high fat diets, providing evidence of ER stress (Figure 16D). 
 
II.D.3. Reversal of ER Stress in Pdx-1 Haploinsufficient Mice with Restoration 
of SERCA2b Protein Levels 
Isolated islets from high-fat diet fed Pdx-1+/- mice and wild type littermates were 
transduced with SERCA2b adenovirus or a LacZ control adenovirus. Successful 
transduction was verified by immunoblot (Figure 17A). With restoration of SERCA2b 
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Figure 15. SERCA2b is decreased in islets isolated from Pdx-1 haploinsufficient 
mice. Pdx-1 haploinsufficient mice and wild type littermates fed a chow diet containing 
17% of kilocalories from fat. A) Intraperitoneal glucose tolerance tests (IPGTT) were 
performed at 11 weeks of age in Pdx-1 haploinsufficient and wild type littermates. B) 
Area under the curve of IPGTT was quantified. C-E) Protein and RNA isolated from 13-
week old Pdx-1 haploinsufficient and wild type littermate mouse islets. C) Representative 
immunoblot using antibodies against SERCA2, Pdx-1, and actin. D) Quantitative protein 
levels as measured by immunoblot. E) Islet mRNA measured by real-time PCR for 
quantification of SERCA2b and Pdx-1. Indicated comparisons are significantly different 
(*p < 0.05, **p < 0.01) by t-test or by multiple t-test with Sidak-Bonferroni post-test. 
Results are displayed as the means ± S.E.M. 
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Figure 16. ER stress observed in islets isolated from diabetic Pdx-1 
haploinsufficient mice fed a high fat diet.  Pdx-1 haploinsufficient (Pdx-1+/-) mice and 
wild type littermates were fed a high fat diet containing 45% kilocalories from fat for 8 
weeks prior to islet isolation. A-B) Protein was isolated from 13-week old Pdx-1+/- and 
wild type littermate control mouse islets. A) Immunoblot was performed using antibodies 
against SERCA2, Pdx-1, and actin. B) Quantitative protein levels are shown graphically. 
C-D) RNA isolated from high fat diet fed Pdx-1+/- and wild type littermate mice was 
quantified by real-time PCR. C) Measurements of Pdx-1 and SERCA2b mRNA from 
isolated islets. D) Measurements of total and the ratio of spliced-to-total Xbp1 RNA from 
isolated islets. Indicated comparisons are significantly different (*p < 0.05, **p < 0.01) or 
not significant (n.s.p > 0.05) by multiple t-tests with Sidak-Bonferroni post-test. Results 
are displayed as the means ± S.E.M. 
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expression in the islets of high-fat diet fed Pdx-1+/- mice, the ratio of spliced-to-unspliced 
Xbp1 was significantly reduced (Figure 17B). 
 
II.E. PPARγ and Pdx-1 Bind the SERCA2 Promoter in Close Proximity 
Previous research in this laboratory has shown that there is a PPAR Response 
Element (PPRE) that allows PPARγ to bind the proximal region of the SERCA2 
promoter. This established PPRE is 13 nucleotides upstream from the Pdx-1 binding site 
investigated in the previously illustrated luciferase and chromatin immunoprecipitation 
experiments (Figure 12B, 14A). The proximal SERCA2 promoter binding sites for Pdx-1 
and PPARγ are in close proximity. 
Other investigators have previously established that Serine-273 phosphorylation of 
PPARγ prevents enhancement of transcription in adipocytes but does not prevent 
binding of PPARγ to a target promoter. We hypothesized that steric hindrance arising 
from this post-translational modification of PPARγ may prevent the recruitment of Pdx-1 
to the proximal SERCA2 promoter.  
 
II.E.1. The PPARγ and Pdx-1 Binding Sites in the SERCA2 Promoter Are 
Situated in Close Proximity 
The region of the SERCA2 promoter containing both the established PPRE and the 
proximal Pdx-1 binding site has strong homology between human, rat and mouse 
species, and the two binding sites are also located near to one another along the linear 
DNA sequence of the SERCA2 promoter (Figure 18A). The predicted crystal structure 
of Pdx-1 derived from a partial crystal resolution combined with structure prediction 
software is available, and when this predicted Pdx-1 structure is computationally docked 
with the established PPARγ structure eight of the ten most probable predicted docking  
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Figure 17. Reconstitution of SERCA2 expression ameliorates ER stress in islets 
isolated from Pdx-1 haploinsufficient mice fed a high fat diet.  Pdx-1+/- mice and wild 
type littermates were fed a high fat diet containing 45% kilocalories from fat for 8 weeks 
prior to islet isolation. A) Immunoblot demonstrating successful adenoviral 
overexpression of SERCA2b in islets isolated from Pdx-1+/- mice and littermate controls 
fed high fat diet. B) Quantification of the ratio of spliced-to-unspliced Xbp1 mRNA in 
isolated islets from high fat diet fed Pdx-1+/- and control mice following SERCA2b 
adenoviral transduction, compared to no virus and to LacZ-expressing control virus. 
Indicated comparisons are significantly different (*p < 0.05, **p < 0.01). n=6 or greater. 
Results are displayed as the means ± S.E.M. 
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conformations place Pdx-1 adjacent to the Serine-273 phosphorylation site of PPARγ, 
one example of which is shown (Figure 18B).  
 
II.E.2 The PPARγ Agonist Pioglitazone Augments Pdx-1 Enhancement of 
SERCA2 Promoter Activity 
Previous work from this laboratory established that the thiazolidinedione drug 
pioglitazone increased transcription of SERCA2 in the β cell [155]. If Pdx-1 and PPARγ 
cooperate at the SERCA2 promoter, combining Pdx-1 transfection with pioglitazone 
treatment should result in increased luciferase signal from a SERCA2-luciferase 
construct containing both binding sites. In a preliminary experiment, cells transfected 
with both a SERCA2-luciferase reporter and Pdx-1 and treated with pioglitazone had 
increased luciferase activity compared to cells not treated with pioglitazone (Figure 
19A).  
 
II.F. Forkhead Box Protein 1 (FOXO1) Inhibits SERCA2 Transcription 
In silico analysis of the SERCA2 promoter also revealed a putative FOXO1 binding 
site 1333 base pairs (bp) upstream of the transcription start site (TSS) (Figure 20A). 
Although FOXO1 could inhibit SERCA2 transcription by decreasing both Pdx-1 and 
PPARγ levels in the β cell [333, 335], the presence of a putative FOXO1 binding site in 
the SERCA2 promoter suggests the possibility that inhibition of SERCA2 transcription by 
FOXO1 might also be direct. When the full-length human SERCA2-luciferase construct 
was co-transfected into NIH-3T3 cultured mouse fibroblasts along with empty vector, 
FOXO1, Pdx-1 or a combination of these plasmids (Figure 20B), Pdx-1 alone increased 
luciferase activity as observed in prior experiments, however co-transfection with 
FOXO1 diminished this relative increase significantly. FOXO1 co-transfection did not 
result in a significant change in luciferase activity compared to empty vector control. 
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Figure 18. PPARγ and Pdx-1 binding sites in the proximal region of the SERCA2 
promoter. The established PPRE in the SERCA2 promoter is known to bind PPARγ, 
and the proximal putative Pdx-1 binding site in the SERCA2 promoter is nearby. A) DNA 
sequence illustrating the proximal SERCA2 promoter region and the respective PPARγ 
and Pdx-1 binding sites. B) Representative ribbon structure diagram illustrating one of 
ten probable docking configurations between Pdx-1 (cyan) and PPARγ (green) proteins, 
with an approximate location of the PPARγ phosphorylatable Serine-273 residue 
(fuchsia) highlighted. 
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Figure 19. Luciferase reporter activity enhanced by Pdx-1 transfection, 
pioglitazone treatment. A) NIH-3T3 cells were co-transfected with a SERCA2-
luciferase construct combined with Pdx-1 plasmid, and treated with pioglitazone. 
Indicated comparisons are significantly different (*p < 0.05) by multiple t-test with Sidak-
Bonferroni post-test. n=4 or greater. Results are displayed as the means ± S.E.M. 
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Figure 20. Luciferase reporter activity enhanced by Pdx-1 transfection, but 
enhancement decreased with FOXO1 co-transfection. A) Inter-species homology in 
the region of the putative FOXO1 binding site in the SERCA2 promoter, B) NIH-3T3 cells 
were co-transfected with a SERCA2-luciferase construct combined with empty vector, 
FOXO1, Pdx-1 or a combination of those plasmids. Indicated comparisons are 
significantly different (**p < 0.01), or not significant (n.s.p > 0.05) by one-way ANOVA with 
multiple comparisons. n=2 per condition. Results are displayed as the means ± S.E.M. 
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Chapter III. Discussion 
A single β cell synthesizes approximately one million insulin molecules per minute - 
an arduous task that requires an extremely well-developed and highly functional ER 
[347].  ER stress in the pancreatic β cell is well appreciated in the context of obesity and 
Type 2 diabetes [348, 349], while more recent and emerging data suggest an expanding 
role for ER stress in the development and progression of Type 1 diabetes [136, 350, 
351]. A key determinant of ER homeostasis is the maintenance of a robust intraluminal 
Ca2+ pool [157, 352].  This pool serves as an important store for Ca2+ release and 
activation of a variety of signaling pathways, including incretin-induced insulin secretion 
[353, 354].  Moreover, ER Ca2+ plays a pivotal role in protein processing and maturation 
through regulation of protein chaperone activity as well as the formation of chaperone 
complexes [157], while depletion of ER calcium inhibits protein synthesis and facilitates 
protein degradation [137-142].  Elegant studies have also illustrated a strict requirement 
for ER-derived Ca2+ in proinsulin processing in secretory granules, where Ca2+ is needed 
for maturation and activity of the endopeptidases prohormone convertase 1 (PC1) and 2 
(PC2) [355, 356].  
The SERCA family of ion pumps serves as a primary gatekeeper of this ER calcium 
gradient.  In one catalytic cycle, SERCA transports two Ca2+ ions into the ER at the 
expense of one ATP molecule. At least three SERCA isoforms are known to be 
expressed in the pancreatic β cell; SERCA2a, 2b, and SERCA3.  Whereas we have 
previously shown that expression of all three isoforms is decreased in islets isolated 
from diabetic rodents [201], this series of experiments was focused on the SERCA2b 
isoform as it is the most highly expressed isoform in mouse islets [357].  Furthermore, 
SERCA2b is structurally unique among all other isoforms because it possesses an extra 
transmembrane domain that imparts it with the highest calcium affinity [200].  Our 
previous work has shown that altered SERCA2b expression leads to altered insulin 
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secretion, activation of ER stress signaling, and decreased β cell survival [357].  The 
goal of this work was to identify additional transcriptional pathways that underlie 
dysregulated SERCA2b expression under inflammatory and diabetic conditions.  
The homeobox protein Pdx-1 or IPF1 plays an essential role in pancreatic and β cell 
development, and the maintenance of postnatal β cell function, including transcriptional 
regulation of insulin gene transcription and other key genes involved in stimulus-
secretion coupling [248, 271, 344].  Pdx-1 also plays a central role in β cell adaptation to 
metabolic stress, and Pdx-1 haploinsufficiency superimposed on a background of severe 
insulin resistance secondary to heterozygous deletion of the insulin receptor and insulin 
receptor substrate 1 leads to impaired compensatory β cell mass expansion, diabetes 
and premature mortality [271]. Sachdeva and colleagues examined the effects of diet-
induced obesity in Pdx-1+/- mice and similarly found that Pdx-1 haploinsufficiency 
significantly limits β cell mass expansion under high-fat diet conditions. Interestingly, 
these effects were not secondary to decreased proliferation, but rather they were due to 
impaired β cell survival. In addition, isolated islets from HFD-fed Pdx-1+/- mice 
demonstrated activation of ER stress signaling pathways and similar results were seen 
in Pdx-1 deficient MIN6 cells. Microarray studies were performed in MIN6 cells 
transduced with adenovirally-expressed shRNA against Pdx-1 and revealed alterations 
in a large subset of genes with well-defined roles in the maintenance of ER function and 
UPR signaling, including Atf4, Wfs1, Ero1b, neuronatin (Nnat), and Heat shock 70kDa 
protein 5 (Hspa5/Bip).  Pdx-1 was confirmed to directly bind the promoters of Atf4 and 
Wfs1, further confirming its role in maintenance of a specific β cell ER subgenome [170].  
Alterations in the expression of Ero1lb and Nnat were confirmed in both Pdx-1 deficient 
MIN6 cells and islets isolated from Pdx-1+/- mice, although these genes were not 
identified as direct transcriptional targets [358, 359].  
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In addition to key ER-related genes previously identified, our results suggest that 
altered SERCA2b expression with concomitant alterations in ER Ca2+ contribute to ER 
stress observed in Pdx-1 deficient states. Here, we show that Pdx-1 and SERCA2b 
expression are altered in parallel in cadaveric human islets, in db/db islets and in an in 
vitro model of inflammatory diabetes. To test whether Pdx-1 directly regulates SERCA2b 
expression, overexpression and knockdown strategies were employed in NIH-3T3 and 
INS-1 cells, respectively.  Results showed that Pdx-1 overexpression increases 
SERCA2b expression, while siRNA-mediated knockdown of Pdx-1 leads to a reciprocal 
reduction in SERCA2b.  Luciferase assays and ChIP assays suggest this relationship is 
direct and show that Pdx-1 binds a proximal region of the human SERCA2 promoter.   
Importantly, we recapitulated the stress paradigm employed by Sachdeva et al. [170] 
and treated Pdx-1+/- mice with a high-fat diet with the goal of determining whether 
reconstitution of SERCA2b in islets ex vivo is sufficient to reverse ER stress secondary 
to Pdx-1 deficiency. Indeed, we show that restoration of SERCA2b expression is 
capable of mitigating ER stress, using spliced XBP-1 as a readout.   
 A novel aspect of our study is that we link modulation of  Pdx-1 expression 
directly with alterations in β cell Ca2+ homeostasis.  Specifically, using a genetically 
encoded and ER localized cameleon reporter [341], our results show that ER Ca2+ is 
decreased in a Pdx-1 deficient state.  In parallel, cytosolic Ca2+ is increased, consistent 
with a deficiency in ER Ca2+ pump function.  While our proposed model would suggest 
these changes are the result of alterations in SERCA2b expression and activity, previous 
literature has shown that Pdx-1 also enhances transcription of the WFS1 gene. WFS1 is 
a transmembrane protein that has been localized to the β cell ER, plasma membrane, 
and secretory granules [360, 361].  Mutations in this gene lead to Wolfram or DIDMOAD 
syndrome in humans, a disorder characterized by childhood onset of diabetes, 
hypoinsulinemia, diabetes insipidus, optic atrophy, and deafness [362, 363], while single 
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nucleotide polymorphisms in Wfs1 have also been linked to T2D susceptibility in human 
populations [364]. Mouse models of diminished Wfs1 exhibit β cell apoptosis due to ER 
stress as well as decreased insulin secretion [365, 366].  The precise function of WFS1 
in the β cell has remained somewhat enigmatic, though recently WFS1 was shown to 
play a role in cyclic AMP production, through translocation from the ER to the plasma 
membrane where it forms a complex with adenylyl cyclase 8 [361].  This protein has also 
been linked to the regulation of ER calcium, raising the possibility that a component of 
our calcium phenotype could be secondary to Wsf1 deficiency [367]. 
Notwithstanding this potential caveat, our results identify SERCA2b as a novel 
transcriptional target of Pdx-1 and identify an additional transcriptional pathway through 
which SERCA2b expression is altered in the β cell under diabetic conditions, and 
moreover demonstrate that ER Ca2+ regulation is altered in Pdx-1 deficient states. 
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Chapter IV. Relevance and Future Directions  
IV.A. Novel Findings and Proposed Investigations 
This work has demonstrated that Pdx-1 enhances SERCA2b transcription in the β 
cell. Previous work in the field has shown that diminished Pdx-1 results in β cell ER 
stress, and these results establish decreased β cell SERCA2b as a contributing 
mechanism for this observed ER stress.  These results further provide evidence that 
restoration of SERCA2b expression in islets is sufficient to reverse ER stress due to 
Ca2+ dysregulation with Pdx-1 haploinsufficiency. These findings regarding Pdx-1 and 
SERCA2b are novel contributions to the field, and they also open further inquiries into 
the transcriptional regulation of SERCA2b in the β cell. 
 
IV.A.1. Proposed Investigation: Pdx-1 and PPARγ Effect on SERCA2b 
In silico analysis provided the clue that Pdx-1 might be a transcriptional enhancer of 
SERCA2b, but this analysis provided other clues as well. The proximal predicted binding 
site for Pdx-1 in the SERCA2 promoter is located near an established PPAR response 
element (PPRE). These experimental results verified that Pdx-1 does bind the most 
proximal putative Pdx-1 binding element, which introduces the possibility of interaction 
between Pdx-1 and PPARγ at the SERCA2 promoter. Investigating the interrelationship 
of PPARγ and Pdx-1 at the SERCA2 promoter is a potential future direction of 
investigation. 
 
IV.A.2. Proposed Investigation: Pdx-1 and FOXO1 Effect on SERCA2b 
Another protein of interest suggested by in silico analysis of the SERCA2 promoter is 
FOXO1, which is antagonistic to Pdx-1 in the β cell [334]. FOXO1 causes Pdx-1 to be 
exported from the nucleus and degraded in the cytosol [333], suggesting that FOXO1 
might decrease SERCA2 transcription. FOXO1 also inhibits PPARγ transcriptional 
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activity in the β cell [335]. If the putative FOXO1 binding site in the SERCA2 promoter is 
valid, then direct binding of FOXO1 to the SERCA2 promoter should inhibit SERCA2 
transcription. 
 
IV.B. Co-localization of PPARγ and Pdx-1 at the SERCA2 Promoter 
Both PPARγ and Pdx-1 are known to form complexes to enhance transcription, 
though it has not previously been hypothesized that they cooperate with one another. If 
these two proteins do interact it may explain an unknown mechanism related to PPARγ 
function in the β cell. When PPARγ is phosphorylated at Serine-273 by CDK5 it is not 
prevented from binding the target gene promoters, but it does fail to enhance 
transcription of those genes [306], and this may also be the mechanism of PPARγ 
inhibition at the SERCA2 promoter. If this phosphorylation causes steric hindrance it 
would prevent co-factors from also binding the promoter, and Pdx-1 could be one such 
co-factor inhibited by steric hindrance. Future studies will be designed to investigate 
whether PPARγ phosphorylation at Serine-273 inhibits recruitment and/or binding of 
Pdx-1 to the SERCA2 promoter. 
 
IV.B.1. Additional Pdx-1 Binding Sites in the SERCA2 Promoter 
The first step in determining whether Pdx-1 and PPARγ interact in the proximal 
region of the SERCA2 promoter is to determine whether Pdx-1 binds at any other 
putative Pdx-1 binding sites. Although promoter analysis studies including ChIP and 
luciferase with both wild-type and mutated SERCA2 promoter sequences indicated that 
the proximal site is bound by Pdx-1, these studies did not exclude any other putative 
Pdx-1 binding sites, of which there are four. If Pdx-1 binds any of the other putative sites 
then it would complicate, but not prevent, the study of the interaction between PPARγ 
and Pdx-1.  
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Figure 21. Experimental plan for future investigation of potential steric hindrance 
of Pdx-1 binding to the SERCA2 promoter due to PPARγ phosphorylation at 
Serine-273. The mechanism of inhibition via phosphorylation of PPARγ at Serine-273 in 
the β cell has not been established. We hypothesize that steric hindrance or electrostatic 
interference prevents formation of a transcriptional complex including Pdx-1 and PPARγ 
at the SERCA2 promoter. We suggest that the listed experiments would provide 
evidence to support or refute this hypothesis. 
  
65 
 
IV.B.1.A. SERCA2-Luciferase Construct Mutation and Pdx-1 
As an initial step to determine whether Pdx-1 binds other locations on the SERCA2 
promoter, additional mutation of a SERCA2-luciferase constructs would be necessary. If 
the proximal site were to be mutated on a SERCA2-luciferase construct containing all 
five elements, and during a luciferase experiment the enhancement of transcription was 
eliminated by mutation of the proximal promoter only, then that would suggest that the 
proximal site is the only relevant one.  
 
IV.B.1.B. Pdx-1 Chromatin Immunoprecipitation 
The initial ChIP experiment detailed in Results only tested for amplification of the 
most proximal region of the SERCA2 promoter. by using qPCR primers that amplify 
incrementally more distal regions of the SERCA2 promoter we would determine which 
regions can be precipitated with Pdx-1 antibody. If this “promoter walking” were to detect 
amplification of distal SERCA2 promoter regions it would provide evidence that Pdx-1 
binds additional putative Pdx-1 binding sites.  
 
IV.B.1.C. Interpreting the Results 
The proposed luciferase and promoter walking ChIP studies will provide evidence of 
whether Pdx-1 binds additional putative sites in the SERCA2 promoter, and if Pdx-1 
binds additional sites then the experimental plan would be adjusted to account for this. 
 
IV.B.2. Models of Pdx-1 Decrease and PPARγ Phosphorylation at Serine-273 
Prior to proceeding with further investigations of the interaction between Pdx-1 and 
PPARγ at the SERCA2 promoter it would be necessary to establish in vitro and in vivo 
models of diabetic conditions. The foundation of any biological investigation must be a 
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thorough understanding of the models to be used, as well as proof that the experimental 
endpoints can be accurately and precisely measured. 
 
IV.B.2.A. In Vitro Model of the β Cell in the Diabetic Milieu 
This laboratory has previously cultured INS-1 832/13 rat insulinoma cells under in 
vitro conditions representing the hyperglycemic and inflammatory milieu of DM. Once 
again, we would culture INS-1 cells in 25 mM glucose and 5 ng/mL of IL-1β cytokine, 
expecting to observe a relative decrease in Pdx-1 levels and a relative increase in the 
phosphorylation of PPARγ Serine-273.  
 
IV.B.2.B. Ex Vivo Model of the β Cell in the Diabetic Milieu 
The Pdx-1 haploinsufficient mouse model is available, and the phenotype of this 
mouse model was previously described in the Results section. Islets isolated from both 
Pdx-1+/- and wild type littermates would be useful for investigations of the interaction 
between Pdx-1 and PPARγ. Treating of the islets ex vivo with high glucose and 
cytokines has previously been performed in this laboratory, and treating mouse islets 
with the PPARγ agonist pioglitazone has also been done previously [155]. Pdx-1+/- 
isolated islets would be treated with pioglitazone and SERCA2b expression levels 
compared to controls. 
 
IV.B.2.C. Expected Results and Potential Challenges 
Both INS-1 cells and islets would be treated with high glucose and cytokines to 
observe a decrease in Pdx-1 protein levels and an increase in PPARγ phosphorylation 
at Serine-273. The cells and islets would also be treated with pioglitazone and the 
effects on both Pdx-1 and PPARγ phosphorylation observed. It is expected that 
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treatment of Pdx-1+/- islets with pioglitazone would have decreased efficacy compared to 
islets from wild type mice.  
If there were no differences, or if the differences were not as expected, then alternate 
models would be selected. For cultured cells MIN-6 mouse insulinoma cells could be 
substituted for INS-1 cells. A cytokine mix including IL-1β as well as interferon gamma 
and tumor necrosis factor alpha could be used instead of IL-1β alone. Other mouse 
models of DM could also be selected, including streptozotocin-treated (STZ) mice or 
db/db mice, where SERCA2b expression is similarly altered. 
 
IV.B.3. Pdx-1 and PPARγ Phosphorylation at Serine-273 
Once the in vitro and isolated islet models were established, and assuming a 
correlation between Pdx-1 and PPARγ was observed, the possibility of a direct 
relationship between Pdx-1 and PPARγ would be investigated. A critical tool for this 
aspect of the investigation would be a phosphomimetic version of PPARγ, wherein the 
Serine residue at the 273rd position would be mutated into Aspartate (PPARγS273D). This 
phosphomimetic protein would be used in co-immunoprecipitation and luciferase studies. 
 
IV.B.3.A. Co-Immunoprecipitation of Pdx-1 and PPARγ 
As a first step, co-immunoprecipitation (Co-IP) of PPARγ and Pdx-1 would be 
pursued. Co-IP would be undertaken both with the native PPARγ protein and with the 
PPARγS273D phosphomimetic mutant.  
 
IV.B.3.B. Luciferase Study With Pdx-1 and PPARγ 
Preliminary experiments using the SERCA2-luciferase construct with pioglitazone 
and Pdx-1 have already been performed, and the results are suggestive of cooperation 
between these two factors. The preliminary experiments would be repeated, and the 
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PPARγS273D phosphomimetic would also be used for additional luciferase studies. 
Additionally SERCA2-luciferase constructs with either the Pdx-1 or the PPARγ binding 
sites mutated would be used with either or both plasmids, and with the PPARγS273D 
phosphomimetic. Fortunately PPARγ expression in NIH-3T3 mouse fibroblasts is 
relatively low [368] so the predominant PPARγ isoform would be the PPARγS273D mutant. 
 
IV.B.3.C. Mouse Islet Transduction with Pdx-1 and PPARγS273D Phosphomimetic 
Pdx-1 enhances transcription of SERCA2, therefore transduction of Pdx-1 into islets 
is expected to increase SERCA2b expression and reduce ER stress as measured by the 
spliced-to-unspliced Xbp1 mRNA ratio. Simply transducing the islets with Pdx-1 would 
not demonstrate cooperativity with PPARγ, however, so a further step must be 
undertaken. Islets would also be transduced with the PPARγS273D phosphomimetic 
mutant as well as Pdx-1 adenovirus to more fully investigate the relationship between 
them. 
 
IV.B.3.D. Expected Results and Potential Challenges 
A successful Co-IP would provide evidence that the two proteins physically interact, 
and if the PPARγS273D phosphomimetic failed to precipitate with Pdx-1 under the same 
conditions, this finding would support the steric hindrance hypothesis. If we did not 
succeed at co-precipitating Pdx-1 and PPARγ that would not be evidence that the two 
proteins do not interact, but rather it might simply signify that our precipitation conditions 
or our antibodies were not conducive to Pdx-1 and PPARγ interaction. Flag-tagged 
proteins could be used to attempt to address antibody concerns.   
As for the luciferase experiments, preliminary results suggest that the effect of 
PPARγ and Pdx-1 are additive, however those experiments were done with pioglitazone 
and not PPARγ plasmid. If the PPARγ and Pdx-1 enhancement effects were found to be 
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multiplicative it would be evidence that the interaction between PPARγ and Pdx-1 is 
more important than either protein alone. The luciferase results obtained with the 
PPARγS273D phosphomimetic would be interesting in that if the phosphomimetic 
decreased the increase in luciferase signal from Pdx-1 then that would be evidence that 
Pdx-1 is subject to interference from PPARγ phosphorylation at Serine-273. If the 
PPARγS273D did not inhibit the Pdx-1 increase in luciferase construct with a mutated 
PPRE that would add further support to the steric hindrance hypothesis. Co-transduction 
of PPARγ and Pdx-1 should result in a greater increase of SERCA2 transcription than 
with either factor alone. If transduction of the PPARγS273D phosphomimetic mutant 
prevented or inhibited the increase of SERCA2 transcription due to co-transduction of 
Pdx-1 that would provide evidence that the interaction of Pdx-1 and PPARγ was relevant 
to SERCA2 transcription in vivo. 
 
IV.C. Inducible PPARγ Serine-273-Aspartate Phosphomimetic Mouse Model 
Mouse models heterozygous for PPARγ are available, as are mice with inducible 
Cre-Lox PPARγ deletion, however a mouse model representing inhibitory 
phosphorylation of PPARγ is not commercially available. Under stress conditions PPARγ 
is phosphorylated by CDK5 at the Serine-273 residue in the β cell, therefore an inducible 
PPARγS273D phosphomimetic mouse model could be used to investigate the role of 
PPARγ in β cell stress response mechanisms. include a transgenic construct with LoxP 
sites flanking the wild-type PPARγ gene as well as flanking a stop codon preventing 
transcription of the mutated PPARγS273D gene. Crossing this mouse with a Mouse Insulin 
Promoter and Cre Recombinase gene (MIP-Cre) would result in a β cell-specific 
inducible model of PPARγ pseudo-phosphorylation. Verification of induction would be via 
qPCR using primers specific to either wild type PPARγ or the PPARγS273D mutant. 
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Figure 22. Mouse model of inducible phosphomimetic PPARγ via mutation of 
Serine-273 to Aspartate. The proposed mouse model of inducible phosphomimetic 
PPARγS273D would include Lox sites flanking a wild-type PPARγ gene as well as a stop 
codon preventing transcription of the mutated PPARγS273D gene. Crossing the mouse to 
a MIP-Cre line and then inducing Cre expression with tamoxifen would result in a β cell-
specific inducible model of PPARγ pseudo-phosphorylation at amino acid 273. 
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 Figure 23. Characterization and investigations using the MIP-Cre PPARγS273D 
mouse model. This MIP-Cre inducible mouse model would remove the wild type PPARγ 
and replace it with PPARγS273D specifically in the β cell when treated with tamoxifen. First 
characterization of the overall metabolic phenotype would be required followed by 
quantification of Pdx-1, SERCA2b, PPARγ, and PPARγS273D protein and mRNA. Isolated 
islets would then be transduced with Pdx-1 adenovirus or treated with the Pdx-1 inducer 
BRD7552 after which SERCA2b levels between PPARγS273D and control islets would be 
compared. 
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IV.C.1. Phenotype of the MIP-Cre PPARγS273D Mouse 
Existing mouse models of PPARγ knockdown are homozygous lethal, and tissue-
specific knockdown is also generally studied in heterozygotes [369]. Characterization of 
this new mouse model’s metabolic phenotype would therefore compare controls to both 
heterozygous and homozygous inducible mutants. Random blood glucose 
measurement, glucose tolerance tests, and insulin tolerance tests would be used to test 
for diabetes, while islet histology would be used to observe and quantify islet and β cell 
mass. Those mice with the most diabetic phenotype would be considered optimal and 
would be used as models of β cell stress for subsequent experiments. 
 
IV.C.2. Isolated Islets from the MIP-Cre PPARγS273D Mouse 
Pancreatic islets would be isolated from experimental and control mice, and qPCR 
primers designed to detect PPARγS273D but not PPARγ would be used to verify induction.  
Protein immunoblot and qPCR would be used to measure Pdx-1, PPARγ, and SERCA2b 
protein and mRNA levels, while spliced and unspliced Xbp1 mRNA transcripts would be 
used to measure relative ER stress. 
 
IV.C.3. Adenoviral Transduction of Islets from the MIP-Cre PPARγS273D Mouse 
Isolated islets from induced PPARγS273D and control mice would be transduced with 
Pdx-1 adenovirus after which SERCA2b protein and mRNA levels would be measured 
and compared to controls. The ratio of spliced to unspliced Xbp1 would be used to 
quantify the extent of ER stress reduction with Pdx-1 transduction. 
 
IV.C.4. Drug Treatment of Islets from the MIP-Cre PPARγS273D Mouse 
Pioglitazone and other TZDs are known agonists of PPARγ, however until recently 
small molecule agonists of Pdx-1 have not been available. The compound BRD7552 
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increases expression of Pdx-1 in β cells [370], and the effect of BRD7552 on SERCA2b 
expression and ER stress would be compared between PPARγS273D and control islets. 
Isolated islets would also be subjected to in vitro high glucose and cytokine stress while 
being treated with either or both compounds, after which levels of PPARγ, Pdx-1 and 
SERCA2b protein and mRNA would be quantified and compared between PPARγS273D 
and control islets. 
 
IV.C.5. Expected Results and Alternatives 
We expect that the PPARγS273D mice will become glucose intolerant due to β cell 
defect, however if a suitable phenotype is not observed then the mice would be fed a 
diet with 45% of kilocalories from fat. An additional option would be to cross the MIP-Cre 
PPARγS273D mice with Pdx-1 haploinsufficient mice to compare the compound 
phenotype. 
We expect that islets isolated from PPARγS273D mice will have decreased levels of 
Pdx-1 and SERCA2b protein and mRNA, since PPARγ is a transcriptional enhancer of 
both of those proteins. We further expect that the ratio of spliced-to-unspliced Xbp1 
mRNA will be higher in PPARγS273D islets. Treatment of PPARγS273D islets with the Pdx-1 
inducer BRD7552 should enhance transcription of SERCA2b in treated islets, however 
we predict that BRD7552 should have a decreased benefit in PPARγS273D islets 
compared to controls. 
Expression of other genes transcriptionally enhanced by PPARγ in the β cell would 
be measured via qPCR to determine the effect of the PPARγS273D  phosphomimetic on 
other proteins in the β cell. One gene directly enhanced by the PPARγ agonist is the 
insulin receptor substrate 1 gene IRS1, and additional genes that are secondarily 
enhanced are INS1, INS2 and GLUT2 [303]. If qPCR of these transcripts did not reveal a 
clear effect of PPARγS273D  then the methylation activity of SET-Domain Containing 
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Histone-Lysine N-Methyltransferases 7 and 9 could also be measured as a surrogate for 
relative PPARγ activity. 
 
IV.D. FOXO1 and the SERCA2 Promoter 
In silico analysis predicted that Pdx-1 binds to the SERCA2 promoter, and these 
results demonstrated that is indeed the case. In silico analysis also predicts that FOXO1 
may bind the SERCA2 promoter. If FOXO1 binds the SERCA2 promoter and inhibits the 
transcription of SERCA2 it might do so by two mechanisms; by direct transcriptional 
repression, or by indirect repression via downstream effectors, or even by a combination 
of the two.  
 
IV.D.1. FOXO1 in Diabetic Models and Expected Results 
Using the earlier established in vitro model of diabetic stress we would measure what 
effect hyperglycemic and inflammatory stress has on FOXO1 in cultured cells. FOXO1 
protein and mRNA concentrations would be measured via immunoblot and qPCR, and 
cell fractions would also be differentially centrifuged in order to measure FOXO1 nuclear 
localization as a surrogate measure of FOXO1 activity. 
 
IV.D.2. FOXO1 Overexpression and Knockdown 
If FOXO1 is an antagonist of SERCA2b expression then overexpressing FOXO1 by 
viral transduction or plasmid transfection should decrease SERCA2b levels as measured 
by immunoblot or qPCR. Conversely, using siRNA versus FOXO1 should result in either 
an increase of SERCA2b in cultured cells, or amelioration of SERCA2b decrease under 
hyperglycemic and inflammatory conditions. 
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Figure 24. Interactions of Pdx-1, PPARγ and FOXO1 in the β cell. The transcription 
factor FOXO1 has long been established as an antagonist to Pdx-1, and recent evidence 
also suggests it is an antagonist to PPARγ in the β cell. The presence of a FOXO1 
consensus binding sequence in the SERCA2 promoter and the preliminary finding that 
FOXO1 impairs the enhancement of SERCA2 transcription by Pdx-1 suggests that 
FOXO1 may bind the SERCA2 promoter directly to inhibit SERCA2 transcription. 
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Figure 25. Experimental plan for future investigation of FOXO1 direct binding to 
the SERCA2 promoter and inhibition of SERCA2 transcription. FOXO1 inhibits both 
PPARγ and Pdx-1, which are both SERCA2b transcription enhancers in the β cell... In 
addition FOXO1 may have a direct inhibitory effect on SERCA2 transcription by binding 
to the promoter. A series of in vitro and ex vivo tests would be carried out to determine 
the effect of FOXO1 on SERCA2 transcription and whether that mechanism is direct, 
indirect or a combination of the two. 
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IV.D.3. FOXO1 and SERCA2 Promoter Analysis 
Since FOXO1 inhibition of SERCA2b might be indirect instead of direct, promoter 
analysis is required to determine whether the mechanism of FOXO1 inhibition of 
SERCA2 transcription is via direct FOXO1 binding of the SERCA2 promoter. The 
promoter analysis experiments used would be luciferase and ChIP. 
 
IV.D.3.A. FOXO1 and SERCA2-Luciferase Constructs 
Preliminary results transfecting FOXO1 plasmid with the SERCA2-luciferase 
construct demonstrated a significant reduction in luciferase expression. These results 
would be repeated and expanded upon. Although the shortest SERCA2-luciferase 
construct was suitable for experiments involving PPARγ, the putative FOXO1 site is 
distant from the transcription start site and therefore a longer construct would be used 
with FOXO1 alone or in concert with Pdx-1.  
Mutated SERCA2-luciferase constructs could further elucidate the FOXO1 and 
SERCA2b relationship. A construct with a mutated FOXO1 binding site would be 
generated and tested for SERCA2 promoter enhancement as measured by luciferase 
activity. 
 
IV.D.3.B. FOXO1 and SERCA2 ChIP 
ChIP analysis of FOXO1 binding to the SERCA2 promoter would provide direct 
evidence of the mechanism of FOXO1 suppression of SERCA2b expression. Primers for 
distal portions of the SERCA2 promoter will have already been made and tested during 
the “promoter walking” process of testing for distal putative Pdx-1 binding sites.  
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IV.D.3.C. Expected Results 
The preliminary luciferase experiments with FOXO1 were carried out in a cell type 
that did not natively express Pdx-1, suggesting that the inhibitory effect of FOXO1 on 
SERCA2 transcription is not necessarily dependent on inhibiting Pdx-1. We expect that 
FOXO1 would continue to inhibit SERCA2 transcription even in the presence of Pdx-1, 
but immunoblotting would be performed to determine whether the inhibition was due in 
whole or in part to degradation of Pdx-1 by FOXO1. If FOXO1 inhibition is able to 
overcome Pdx-1 enhancement of SERCA2 transcription, we expect that whether or not 
the proximal Pdx-1 site was mutated this inhibition would be consistent, and if the 
mechanism of FOXO1 inhibition is via direct binding then mutation of its binding site 
should eliminate its inhibition effect on SERCA2 transcription. 
As for ChIP with FOXO1 and the SERCA2 promoter, if FOXO1 antibody were to 
precipitate the distal portion of the SERCA2 promoter it would provide further evidence 
that the binding of FOXO1 was direct, and that FOXO1 suppression of SERCA2b 
expression is not dependent only on suppression of Pdx-1 or other SERCA2b enhancing 
factors. ChIP might provide a false negative if FOXO1 is not located in the nucleus, so if 
the cells were stressed immediately prior to lysis that may increase binding of FOXO1 to 
the SERCA2 promoter. Alternatively, exogenous FOXO1 could be transduced into cells 
prior to lysis. Finally, FOXO1 overexpression and knockdown mouse models are 
commercially available and could be used to study the effects of FOXO1 in isolated 
islets. 
 
IV.E. Summary of Future Directions 
ER Ca2+ homeostasis is a matter of life and death to the pancreatic β cell, therefore it 
should come as no surprise that SERCA2b expression is carefully managed by a 
number of transcription factors. The functional effects of SERCA2b regulation are now 
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becoming better understood, but the whole picture remains incomplete. What is the 
mechanism of PPARγ inhibition by phosphorylation at Serine-273? Does the otherwise 
pro-survival FOXO1 transcription factor downregulate SERCA2b expression in the β cell 
under hyperglycemic and inflammatory stress? The answers to these questions are not 
yet known, but understanding these mechanisms would further the field and potentially 
be applicable to other tissue types as well. 
SERCA2a is also downregulated in cardiomyocytes after myocardial infarction, but 
the purpose and mechanism is not fully understood [371]. Restoration of SERCA 
function in cardiomyocytes is known to improve heart function, so increased 
understanding of factors capable of increasing SERCA2 transcription may have 
translational applications not only for DM but also for heart failure [372]. Clinical trial 
results of a drug enhancing SERCA function in heart failure suggest that SERCA2 gene 
therapy may have efficacy improving cardiac function in patients recovering from cardiac 
events [373].  
Lastly, it should be noted that there are ongoing efforts to design therapies to 
activate SERCA2a in myocytes in congestive heart failure including one drug istaroxime 
that has been recently studied in a Phase II trial . Calcium regulation also plays a role in 
cellular differentiation and de-differentiation in a variety of tissue types, including 
myocytes, osteoblasts and neurons [374-376]. Pdx-1 is the most essential transcription 
factor for differentiation of the pancreas from the embryonic foregut, and the extent to 
which this differentiation effect is dependent on Ca2+ regulation is unknown [247]. 
Furthermore, is the Ca2+ dysregulation observed due to a decrease in Pdx-1 and 
concomitant decrease in SERCA2b permissive for β cell dedifferentiation, and thus 
survival? Does Pdx-1 enhancement of SERCA2b contribute to an intracellular Ca2+ 
milieu favorable towards maintenance of mature β cell function? These questions have 
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not yet been explored, but the answers may provide increased understanding of pro-
survival adaptations of the β cell under hyperglycemic and inflammatory stress. 
As for a Cre-Lox model of PPARγS273D phosphomimetic mutation, it could potentially 
have broader application than the study of DM. PPARγ dysfunction is relevant to a 
plethora of diseases including insulin resistance but also lipodystrophy, hypertension, 
vascular nitric oxide signaling, and other diseases [369]. The PPARγS273D 
phosphomimetic mouse model could be used in many other studies in many tissue 
types, and thus it would be a novel mouse model with broad applicability across a host 
of systems to a number of diseases affecting human health. 
For these reasons, and for potential translational applications, increased 
understanding of the effect of Pdx-1 and its cofactors or antagonists on SERCA2 
transcription is an important and novel contribution to the field of β cell biology and its 
role in diabetes mellitus. 
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Chapter V. Experimental Procedures 
Chapter V.A. Animals and Islet Preparations 
Animals were maintained under protocols approved by the Indiana University 
Institutional Animal Care and Use Committee, the U.S. Department of Agriculture’s 
Animal Welfare Act (9 CFR Parts 1, 2, and 3), and the Guide for the Care and Use of 
Laboratory Animals [377]. C57BL/6J-db/db mice and heterozygote littermate controls 
were obtained from Jackson Laboratories (Bar Harbor, ME) at 12 weeks of age. PDX KO 
CC4 Pdx-1 haploinsufficient mice on a mixed background were a generous gift from 
Chris Wright at Vanderbilt University School of Medicine (Nashville, TN), and Pdx-1 
haploinsufficient males were bred to C57BL/6J wild-type dams. Male offspring were 
weaned at age 4 weeks, and at age 5 weeks were either maintained on a normal chow 
diet (17% kcal from fat) or begun on high fat diet (45% kcal from fat) regiment for 8 
weeks, to a total age of 13 weeks.  
Cages were kept in a standard light-dark cycle with ad libitum access to food and 
water. Animals were housed in a secure facility on the premises of the Indiana University 
School of Medicine in plastic cages with sterilized corn-cob bedding. No more than five 
mice and no less than two mice were housed in any cage. Bedding was changed at 
weaning, every 14 days, or after intraperitoneal glucose tolerance testing (IPGTT). 
To determine the Pdx-1 haploinsufficiency genotype, male offspring of PDX KO CC4 
sires were genotyped for the presence of the CC4 gene using a PCR protocol and 
primers obtained from the laboratory of Dr. Chris Wright. Because of the possibility of 
false negatives due to insufficient or low-quality DNA, a separate genotype for the 
SET7/9 gene was run as a positive control. The SET7/9 genotype protocol was chosen 
because this laboratory has previously found it to be robust. Genotype test results were 
counted as accurate if a band for the SET7/9 gene was present, and mice were counted 
as Pdx-1 heterozygotes if a band corresponding to the CC4 gene was detected. 
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IPGTT were performed at 11 total weeks of age using a previously described 
protocol [378, 379]. Briefly, mice were fasted 14 hours overnight, and the following 
morning each mouse was weighed while the initial time-zero blood glucose 
measurement taken. Each individual animal was then injected intraperitoneally with a 
sterile glucose solution corresponding to the mouse’s weight. Blood glucose 
measurements were taken 15, 30, 45, 60, 90 and 120 minutes after injection. 
Random blood glucose was measured in the initial experimental cohort from total 
age 8 weeks to total age 13 weeks to verify a non-diabetic phenotype. For both random 
blood glucose measurements and IPGTT, blood glucose concentration was measured 
using an AlphaTRAK glucometer from Abbott Laboratories (Abbott Park, IL) using blood 
from a small incision in the tail vein. 
  
Chapter V.B. Cell Culture and In Vitro Adenoviral Transduction 
Immortalized cultured cells were used for in vitro experiments, with rat insulinoma 
cells used to in experiments requiring Pdx-1, and mouse fibroblast cells used in 
experiments where endogenous Pdx-1 was undesirable for experimental design 
purposes.  
INS-1 832/13 rat insulinoma cells were cultured as previously described [201, 380]. 
The INS-1 cells were cultured at 37ºC with 5% CO2 in Roswell Park Memorial Institute 
media 1640 containing 11.1 mM glucose supplemented with 10% fetal bovine serum, 
100 U/ml penicillin, 100 μg/ml streptomycin, 10 mM HEPES, 2 mM L-glutamine, 1 mM 
sodium pyruvate, and 50 μM β-mercaptoethanol. When split the cells were trypsinized 
and replated for experimental or passage purposes. INS-1 cells were passaged using 12 
mL of culture media in T-75 flasks, and media was replaced every 24-48 hours. Prior to 
use in experiments INS-1 cells were counted by hemocytometer before plating in cell-
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culture coated 12-well or 6-well plates, with approximately 1.5x105 or 3x105 cells plated 
per well in 12-well and 6-well plates, respectively. 
NIH-3T3 immortalized mouse fibroblast cells were cultured at 37ºC and 5% CO2 in 
Dulbecco’s Modified Essential Medium supplemented with 10% fetal bovine serum, 100 
U/ml penicillin and 100 μg/ml streptomycin [381]. When split the cells were trypsinized 
and replated for either experimental or passage purposes. NIH-3T3 cells were passaged 
in 12 mL of media in T-75 flasks with the media on passaged cells replaced every 24-48 
hours. When used for experiments, NIH-3T3 cells were counted by hemocytometer prior 
to plating in cell-culture coated 12-well or 6-well plates, with between 7.5x104 and 
1.5x105 cells plated per well in 12-well and 6-well plates, respectively. 
This laboratory has previously published an in vitro model of treating cells with 25 
mM glucose and 5ng/mL IL-1β for 24 to test hyperglycemic and inflammatory conditions 
[155]. Briefly, INS-1 cells were split approximately 1.5 x105 cells per well in a 12-well 
coated culture dish. The following day 9 parts fresh INS-1 media (see cell culture 
section) was mixed with 1 part INS-1 media with 151 mM glucose concentration. To this 
high glucose media was added 5 ng/mL of mouse IL-1b inflammatory cytokine then the 
mixed HG+IL-1b media was placed onto the INS-1 cells in lieu of normal media. Cells 
were then cultured for either 16 or 24 hours at 5% CO2 and 37C prior to rinsing with 
PBS and lysis for either quantitative PCR or Western protein immunoblot. 
For adenoviral transduction in cell lines, culture media was replaced with fresh media 
containing an adenovirus expressing either hamster Pdx-1, mouse SERCA2b [382], 
Pdx-1 siRNA [342], random siRNA [383], or a LacZ control virus, followed by 24 hours 
incubation. Interfering RNA sequences used were as follows: siPdx-1: 5’- 
GAAAGAGGAAGATAAGAAA-3’; random siRNA: 5’- GAGACCCTATCCGTGATTA-3’. For 
each experiment approximately equivalent concentration of virus was added for either 
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experimental or control conditions. After 24 hours, RNA or protein was isolated from 
transduced cells for indicated analyses.   
 
Chapter V.C. Isolated Islets and Adenoviral Islet Transduction 
Mice were 13 weeks of age at islet isolation. Islets were isolated by technicians in the 
islet core facility of the Wells Center Diabetes Research Group, using collagenase 
digestion as described previously [384]. Primary islets were suspended in RPMI media 
after isolation, then placed in 6-well uncoated culture dishes and incubated at 37C with 
5% supplemental CO2 for approximately one hour. Islets were visually counted and then 
pooled by genotype. For protein immunoblot approximately 100 islets were selected for 
lysis and purification, and for mRNA isolation approximately 50 islets were selected for 
lysis and purification.  
If islets were to be virally transduced, prior to lysis they were placed into wells of a 
new uncoated culture plate, suspended in Dulbecco’s Modified Essential Medium 
including 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin, and 
incubated with either mouse SERCA2b or LacZ adenovirus for 24 hours, with lysis and 
purification performed the following day. Islets were treated with 5 times the 
concentration used for cultured cells. 
Human islets were obtained from NIDCC. Our analysis included islets from five 
nondiabetic donors and three donors with a previous diagnosis of T2D. The average 
donor age was 48.1 ± 4.2 years (S.E.M.), and the average body mass index (BMI) was 
25.8 kg/m2 ± 2.1 (S.E.M.). Upon receipt, cadaveric human islets were placed at 37C and 
5% CO2 and allowed to acclimate for 24 hours. The following day islets were counted 
and lysed for mRNA isolation in the same manner as mouse islets.  
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Chapter V.D. Protein Immunoblot and Analysis 
Isolated islets or cultured cells were washed with PBS and lysed with buffer 
containing 50mM Tris (pH 8.0), 150 mM NaCl, 0.05% Desoxycholate, 0.1% IGEPAL CA-
630 (Sigma-Aldrich, St. Louis, MO), 0.1% SDS, 0.2% sarcosyl, 10% glycerol, 1mM DTT, 
1mM EDTA, 10mM NaF, EDTA-free “Complete Mini” protease inhibitors (Roche Applied 
Science, Penzburg, Germany), “PhosphoStop” phosphatase inhibitors (Roche Applied 
Science), 2mM MgCl2, and 0.05% v/v benzonase nuclease (Sigma-Aldrich).  Lysate from 
isolated islets was further disrupted by mechanical shearing using a 20 gauge needle 
and syringe.  
Protein concentration was measured using the Bio-Rad DC protein assay (Bio-Rad, 
Hercules, CA) and a SpectraMax M5 multiwell plate reader (Molecular Devices, 
Sunnyvale, CA).  Equal concentrations of proteins were suspended in 10% SDS solution 
and heated to 70C for 5 minutes to more fully denature the proteins prior to 
electrophoresis using a 4-20% Mini-Protean TGX gel in a Mini-Protean Tetra apparatus 
(Bio-Rad). Protein lysates were electrophoresed at room temperature applying 90 volts 
for 90 minutes from a constant voltage power supply. The separated proteins were 
transferred to methanol-activated PVDF membrane at 90 volts for 60 minutes at 
approximately 4C using a constant voltage power supply. Membranes were then protein 
blocked with Odyssey blocking buffer (LI-COR, Lincoln, NE) prior to incubation with 
primary antibodies (Table 1). Dried immunoblot membranes were scanned using a LI-
COR Odyssey 1828 scanner and analyzed with LI-COR Image Studio software (LI-
COR), with densitometry of scanned images calculated by Image-J software (National 
Institutes of Health, Bethesda, MD). Membranes were re-wetted with methanol and 
PBST prior to incubation with a second or third detection antibody. 
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TABLE 1. Immunoblot antibodies and incubation conditions 
Pdx-1 Millipore 07-696 40 hours, 4C, Shaker table 
SERCA2 Santa Cruz sc-8095 40 hours, 4C, Shaker table 
Actin MP Biomed 691002 2 hours, 23C, Shaker table 
GAPDH Abcam ab9484 2 hours, 23C, Shaker table 
 
Table 1. Primary and secondary antibodies used for immunoblot. The proteins of 
interest were Pdx-1 and SERCA2b with actin as a loading control for most experiments, 
with GAPDH used as an alternative loading control for ex vivo immunoblot of isolated 
mouse islets. All antibodies had cross-reactivity for all human, rat and mouse tissues. 
The SERCA2b antibody used is not capable of distinguishing between SERCA2 
isoforms.  
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Chapter V.E. Quantitative Real Time PCR (qPCR) 
Cultured cells or isolated islets were processed for total RNA using RNeasy Mini plus 
or Micro plus kits (Qiagen, Valencia, CA), according to manufacturer’s instructions and 
as described previously [385, 386]. For quantitative RT-PCR experiments, total RNA was 
reverse-transcribed at 37°C for 1 hour using 15 µg random hexamers, 0.5 mM dNTPs, 5X 
first-strand buffer, 0.01 mM DTT, and 200 units of Moloney murine leukemia virus 
(MMLV) reverse transcriptase (all from Invitrogen, Grand Island, NY). Quantitative RT-
PCR was performed as described previously using either SYBR Green I dye and 
previously published primer sequences [342, 386-388], or using TaqMan proprietary 
primers (Life Technologies, Grand Island, NY) (Table 2). 
 
Chapter V.F. Fura-2 AM Cytoplasmic Calcium Imaging 
Approximately 5 x105 INS-1 832/13 cells were seeded in a glass bottom 50 mm plate 
24 hours prior to transduction with siPdx-1 adenovirus, random siRNA adenovirus, or no 
adenovirus for an additional 20 hours.  The cells were then incubated at 37ºC plus 5% 
CO2 in GIBCO Hank’s Balanced Salt Solution (Life Technologies, Grand Island, NY) plus 
Fura-2 AM fluorescent dye (Life Technologies) for one hour.  After Fura-2 AM 
incubation, cells were placed in HBSS without Fura-2 AM and maintained at 37ºC plus 
5% CO2 during imaging.  Random cells in a random field were selected and imaged for 
fluorescence at 340 and 380 nm.  Images were captured using a Zeiss Z1 microscope 
with a 20x objective (Zeiss, Oberkochen, Germany), and results were analyzed with Zen 
Blue software (Zeiss). 
 
Chapter V.G. Fluorescence Lifetime Imaging Microscopy (FLIM) 
A D4ER adenovirus that has been previously published was used for spectrometric 
analysis of ER Ca2+ [341].  This probe was created by replacing the Ca2+ binding domain  
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 TABLE 2. Quantitative PCR primers and temperatures 
SERCA2b 
(mouse) 
Forward: 5’-GATCCTCTACGTGGAACCTTTG-3’ 
Reverse: 5’-CCACAGGGAGCAGGAAGAT-3’ 
1x 95C 10 minutes, 65C 1 
minute; 40x 65C 1 minute, 
60C 30 seconds, 95C 30 
seconds 
SERCA2b 
(rat) 
Forward: 5’-GTGGAACCTTTGCCACTCAT-3’ 
Reverse: 5’-TGTGCTGTAGACCCAGACCA-3’ 
1x 95C 10 minutes, 65C 1 
minute; 40x 65C 1 minute, 
60C 30 seconds, 95C 30 
seconds 
SERCA2b 
(human) 
Forward: 5’-ACAATGGCGCTCTCTGTTCT-3’ 
Reverse: 5’-ATCACCAGGGGCATTATGAG-3’ 
1x 95C 10 minutes, 65C 1 
minute; 40x 65C 1 minute, 
60C 30 seconds, 95C 30 
seconds 
Actin 
(mouse, 
rat, 
human) 
Forward: 5’-AGGTCATCACTATTGGCAACGA-3’ 
Reverse: 5’-
CACTTCATGATGGAATTGAATGTAGTT-3’ 
1x 95C 10 minutes, 65C 1 
minute; 40x 65C 1 minute, 
60C 30 seconds, 95C 30 
seconds 
Total 
Xbp1 
(mouse) 
Forward: 5’- TGGCCGGGTCTGCTGAGTCCG-3’ 
Reverse: 5’- GTCCATGGGAAGATGTTCTGG-3’ 
1x 95C 10 minutes, 65C 1 
minute; 40x 65C 1 minute, 
60C 30 seconds, 95C 30 
seconds 
Spliced 
Xbp1 
(mouse) 
Forward: 5’- CTGAGTCCGAATCAGGTGCAG-3’  
Reverse: 5’- GTCCATGGGAAGATGTTCTGG-3’ 
1x 95C 10 minutes, 65C 1 
minute; 40x 65C 1 minute, 
60C 30 seconds, 95C 30 
seconds 
Pdx-1 
(mouse) Taqman: Mm00435565_m1 
1x 95C 10 minutes, 65C 1 
minute; 40x 65C 1 minute, 
95C 30 seconds 
Pdx-1 
(rat) Taqman: Rn00755591_m1 
1x 95C 10 minutes, 65C 1 
minute; 40x 65C 1 minute, 
95C 30 seconds 
Pdx-1 
(human) Taqman: Hs00236830_m1 
1x 95C 10 minutes, 65C 1 
minute; 40x 65C 1 minute, 
95C 30 seconds 
 
Table 2. Quantitative PCR analysis of messenger RNA. Primers used for mRNA 
analysis in mouse and rat cultured cells, as well as in human and mouse islets. SYBR 
green was used for all mRNA measurements except for measurement of Pdx-1 mRNA, 
which used the proprietary TaqMan combined primer and dye in all three species. 
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of the D1ER construct with D4, to provide lower Ca2+ affinity and placing it downstream 
of the rat insulin promoter.  Briefly, INS-1 cells were cultured for 18 hours with the D4ER 
adenovirus and siPdx-1 adenovirus or random siRNA adenovirus and then allowed to 
recover for 6 hours.  Fluorescence Lifetime Imaging Microscopy (FLIM), was carried out 
in accordance with a previously published protocol [389-391].  The Alba FastFLIM 
system (ISS Inc., Champaign, IL) was coupled to an Olympus IX71 microscope using 
60x water-immersion lens (Olympus, Tokyo, Japan).  Confocal scanning was controlled 
by Build 143 VistaVision software (ISS Inc.) at 530/43 nm acceptor and 480/40 nm 
receptor wavelengths.  Regions of interest were selected with typically >75 count 
average.  Efficiency of Förster Resonance Energy Transfer (FRET) was estimated by 
the following equation: EFRET=1-TDA/TD.  Averaged results per cell were plotted as a 
function of accepted-to-donor ratio (IA/ID).  
 
Chapter V.H. Luciferase Reporter Assay 
A previous publication from this laboratory utilized luciferase constructs incorporating 
different lengths of the human SERCA2 promoter [155], and the same constructs were 
used for this series of experiments.  Approximately 2.0 x104 NIH-3T3 mouse fibroblast 
cells were seeded in 12-well plates 24 hours before transfection. Approximately 200 μg 
of plasmid was transfected into cells using Metafectene Pro transfection reagent (Biotex, 
Munich, Germany) according to manufacturer instructions. During transduction, cells 
remained in GIBCO Opti-MEM transfection media (Life Technologies) for 6 hours, 
followed by incubation for 18 additional hours in normal media and then lysis.  
Total luminescence was measured in triplicate using the Promega Luciferase Assay 
System kit (Promega, Madison, WI) using a SpectraMax M5 plate reader (Molecular 
Devices) in top-read mode of 3000 ms per well.  Luminosity results were normalized to 
total protein content as measured with the same BCA assay technique described for 
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immunoblotting (Bio-Rad). A luciferase construct with a deleted putative proximal Pdx-1 
binding site was created by mutagenesis using the Stratagene QuickChange Site-
Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) according to the 
manufacturer's instructions, and the site-specific deletion was confirmed by automated 
DNA sequencing (GENEWIZ, South Plainfield, NJ).   
 
Chapter V.I. Chromatin Immunoprecipitation (ChIP) 
Approximately 3.25 x106 INS-1 cells were fixed in 1% formaldehyde for 10 minutes, 
sonicated to shear DNA fragments into the size range of 800-2000 bp, and then 
subjected to chromatin immunoprecipitation (ChIP) as detailed previously [155, 387].  
Crosslinked protein and promoters were incubated for approximately 35 hours under 
nutation at 4oC using anti-Pdx-1 antibody sc-14664X (Santa Cruz Biotechnology, Dallas, 
TX) with normal rabbit immunoglobulin G (Santa Cruz Biotechnology) as a control.  
Samples were quantitated in triplicate by SYBR Green I based quantitative real-time 
PCR as previously described [386] using forward and reverse primer sequences for the 
rat SERCA2 promoter with the following sequences: Forward 5’-
CGCTTTTGGCTGTGTGGGAAG-3’, Reverse 5’-TGGTGTCCTTGGCTTGCCTC-3’, the 
rat insulin 1 (INS1) promoter with the following sequences: Forward 5’-
TCAGCCAAAGATGAAGAAGGTCTC-3’, Reverse 5’-GCATTTTCCACATCATTCCCC-3’.   
 
Chapter V.J. Statistical Analysis 
Differences between groups were analyzed for significance using unpaired Student’s 
t-Test, one-way ANOVA with multiple comparisons and Tukey-Kramer post-test, Best-fit 
analysis, or multiple t-Tests with Sidak-Bonferroni correction [392], as calculated by 
GraphPad Prism 6.01 statistics software.  A p value < 0.05 was considered to indicate a 
significant difference between groups.  
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